[{"text": "We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn editorial-team@simplywallst.com (Simply Wall St) Tue, Jan 7, 2025, 5:18 PM 4 min read In This Article: CRVS -5.41% There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Corvus Pharmaceuticals ( NASDAQ:CRVS ) shareholders have done very well over the last year, with the share price soaring by 168%. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. Given its strong share price performance, we think it's worthwhile for Corvus Pharmaceuticals shareholders to consider whether its cash burn is concerning. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. View our latest analysis for Corvus Pharmaceuticals When Might Corvus Pharmaceuticals Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at September 2024, Corvus Pharmaceuticals had cash of US$42m and no debt. Importantly, its cash burn was US$22m over the trailing twelve months. Therefore, from September 2024 it had roughly 23 months of cash runway. Importantly, though, analysts think that Corvus Pharmaceuticals will reach cashflow breakeven before then. In that case, it may never reach the end of its cash runway. Depicted below, you can see how its cash holdings have changed over time. NasdaqGM:CRVS Debt to Equity History January 7th 2025 How Is Corvus Pharmaceuticals' Cash Burn Changing Over Time? Corvus Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. As it happens, the company's cash burn reduced by 16% over the last year, which suggests that management are maintaining a fairly steady rate of business development, albeit with a slight decrease in spending. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . Can Corvus Pharmaceuticals Raise More Cash Easily? While Corvus Pharmaceuticals is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Story Continues Since it has a market capitalisation of US$375m, Corvus Pharmaceuticals' US$22m in cash burn equates to about 5.9% of its market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. How Risky Is Corvus Pharmaceuticals' Cash Burn Situation? As you can probably tell by now, we're not too worried about Corvus Pharmaceuticals' cash burn. For example, we think its cash burn relative to its market cap suggests that the company is on a good path. Its weak point is its cash burn reduction, but even that wasn't too bad! It's clearly very positive to see that analysts are forecasting the company will break even fairly soon. Taking all the factors in this report into account, we're not at all worried about its cash burn, as the business appears well capitalized to spend as needs be. Taking a deeper dive, we've spotted 4 warning signs for Corvus Pharmaceuticals you should be aware of, and 1 of them is a bit unpleasant. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2025-01-07T17:18:50", "sentiment": {"score": 0.023878734558820724, "confidence": 0.08310477435588837, "probabilities": {"positive": 0.08310477435588837, "negative": 0.05922603979706764, "neutral": 0.8576691150665283}}, "embedding": [-0.04126273840665817, -0.044693559408187866, 0.014995692297816277, -0.10768447816371918, 0.032390084117650986, -0.08154287934303284, 0.0328778512775898, 0.10755200684070587, 0.12624989449977875, 0.1292227804660797, -0.0359671451151371, 0.08844257891178131, -0.04792064428329468, 0.02815874107182026, -0.08602038025856018, -0.10081267356872559, -0.09671096503734589, -0.05025818943977356, -0.043481454253196716, 0.08596374839544296, 0.00015462003648281097, -0.0955117791891098, -0.014651449397206306, 0.12884999811649323, 0.04587525874376297, 0.05808454751968384, -0.07852131128311157, 0.016987226903438568, -0.10097676515579224, -0.08897671103477478, 0.07452814280986786, 0.15457454323768616, 0.11229762434959412, -0.0012776637449860573, 0.004199213348329067, 0.048963576555252075, -0.037631187587976456, 0.15118879079818726, 0.06290736049413681, 0.14096277952194214, -0.13954944908618927, -0.06363088637590408, -0.0662667378783226, -0.04052253067493439, 0.023026738315820694, -0.2235681712627411, -0.010978229343891144, 0.0005669118836522102, -0.07593327760696411, 0.17318320274353027, -0.045859042555093765, 0.02874583750963211, -0.02661430463194847, 0.0719202309846878, -0.01555328443646431, 0.0563809908926487, -0.05746615678071976, -0.046052828431129456, -0.01357828825712204, -0.08061893284320831, 0.04290097951889038, 0.00938112847507, 0.06735210120677948, -0.040348656475543976, 0.05841679498553276, 0.03636564686894417, 0.1584760695695877, 0.06366489082574844, -0.08245058357715607, 0.09684047847986221, 0.12651246786117554, -0.04017621651291847, -0.05322626978158951, -0.1199076771736145, -0.13185448944568634, 0.17109712958335876, 0.08075293898582458, 0.13974294066429138, 0.08594521880149841, -0.11465226113796234, 0.17595188319683075, 0.05806604027748108, -0.058691222220659256, -0.08835986256599426, -0.1495051234960556, 0.041633427143096924, 0.14655356109142303, -0.12984973192214966, 0.164923757314682, 0.03730522841215134, 0.02514258213341236, 0.05672049522399902, 0.01902986690402031, -0.05005025863647461, -0.012249262072145939, -0.00356313306838274, -0.06245596334338188, 0.07013074308633804, 0.0645698606967926, -0.022174015641212463, 0.12578773498535156, 0.13395076990127563, -0.06080343946814537, -0.15403328835964203, 0.04073505103588104, -0.08213824778795242, 0.054490361362695694, -0.007579605095088482, 0.043538983911275864, 0.03156135976314545, -0.11485089361667633, 0.1532731056213379, -0.07366694509983063, -0.0970991998910904, 0.09901878982782364, 0.07115306705236435, -0.13444504141807556, -0.06952115148305893, 0.12035788595676422, 0.006390746682882309, 0.1843847632408142, 0.12493240833282471, -0.06180807575583458, -0.06781254708766937, 0.013614138588309288, 0.006421116180717945, -0.053272295743227005, 1.2710660088375735e-32, -0.04544096067547798, 0.03627852350473404, 0.08952108025550842, -0.037696436047554016, -0.08766201138496399, -0.005658846814185381, -0.04911036044359207, 0.015151377767324448, -0.1361539214849472, -0.052009329199790955, -0.08737248927354813, 0.0706760585308075, -0.017764324322342873, -0.056056909263134, 0.013279352337121964, -0.026664581149816513, -0.053557172417640686, -0.10728344321250916, 0.03988227993249893, -0.11504606157541275, -0.09775936603546143, 0.07142719626426697, -0.07168977707624435, 0.059908054769039154, 0.07687172293663025, -0.05870134010910988, -0.11827923357486725, 0.02083495259284973, -0.08069756627082825, 0.020518042147159576, -0.022538581863045692, 0.0719391405582428, -0.01439690962433815, -0.05800995975732803, -0.025357132777571678, -0.03658683970570564, -0.09163941442966461, 0.0032480061054229736, 0.05553737282752991, -0.004704948980361223, -0.02361011505126953, 0.024242836982011795, -0.04834430292248726, -0.062467221170663834, -0.013920055702328682, 0.009537279605865479, -0.05308397859334946, 0.0063269129022955894, -0.08552344143390656, -0.033777058124542236, 0.021719608455896378, 0.0381414033472538, -0.03459187597036362, 0.026816705241799355, -0.033504683524370193, -0.0188122745603323, -0.06277037411928177, -0.17634010314941406, 0.07603354007005692, 0.07776978611946106, 0.06382305175065994, 0.0751604288816452, -0.0785885825753212, 0.03606531769037247, -0.21611946821212769, 0.2194940596818924, 0.025785213336348534, 0.02520669810473919, 0.014895698055624962, 0.03682345896959305, -0.021532880142331123, -0.04785120487213135, 0.08313216269016266, 0.010191609151661396, 0.05648510158061981, -0.03506196662783623, 0.03541670739650726, 0.03243519365787506, -0.046291932463645935, 0.1380627304315567, -0.08786499500274658, -0.08678556978702545, 0.12155609577894211, -0.0104419756680727, 0.009594189003109932, -0.11374235153198242, 0.0909992977976799, -0.05909663811326027, -0.049701035022735596, 0.07893198728561401, -0.04706481844186783, -0.09944269806146622, 0.008441733196377754, 0.1735016107559204, -0.04562508687376976, -1.1922141416580022e-32, 0.037004947662353516, 0.05645991861820221, 0.010959615930914879, 0.019249040633440018, -0.0994613915681839, 0.005103672854602337, 0.09828563779592514, 0.008064737543463707, -0.029366258531808853, -0.12896829843521118, -0.06239195168018341, -0.0068549201823771, -0.15570561587810516, 0.161580428481102, 0.008403683081269264, 0.039495114237070084, 0.1481090784072876, -0.04916782304644585, -0.11071985214948654, -0.011512406170368195, -0.0031689966563135386, 0.15741640329360962, -0.08003615587949753, 0.07918436825275421, -0.04901325702667236, 0.104587122797966, -0.029639270156621933, 0.035503555089235306, -0.02697320468723774, -0.005233078263700008, -0.03911590576171875, -0.036594681441783905, -0.16022007167339325, -0.004023361019790173, -0.0075333211570978165, -0.13301563262939453, -0.029307501390576363, -0.14789843559265137, 0.03390710800886154, -0.10919609665870667, 0.11906363070011139, 0.0620025098323822, -0.021054454147815704, 0.010977634228765965, 0.11948198080062866, -0.07462874054908752, 0.08967278897762299, -0.022332441061735153, 0.22009386122226715, 0.14375212788581848, 0.12279403209686279, -0.003817121498286724, -0.07398487627506256, 0.12891539931297302, -0.03121315687894821, 0.12575311958789825, 0.03990420699119568, -0.05915944278240204, -0.040492042899131775, 0.007801649626344442, 0.03767790645360947, 0.052422136068344116, -0.06934618204832077, 0.043007683008909225, -0.00561152771115303, -0.009512059390544891, -0.01658140867948532, -0.08870276808738708, -0.0009003896266222, -0.0759962871670723, -0.07212677597999573, -0.0041316794231534, -0.007096487563103437, -0.030759315937757492, 0.0006774133071303368, 0.26531144976615906, -0.13673248887062073, -0.14583471417427063, -0.09611968696117401, -0.04326256364583969, -0.09639453887939453, -0.06552361696958542, 0.058438945561647415, 0.024507775902748108, -0.12697738409042358, 0.06145714968442917, -0.08236166089773178, -0.20174485445022583, -0.07375679910182953, 0.026665516197681427, -0.04675130918622017, -0.24524465203285217, -0.08738170564174652, -0.005103260278701782, 0.05522645264863968, -1.0007833139979994e-07, -0.011565279215574265, -0.019169380888342857, 0.08106755465269089, -0.019881542772054672, 0.18138061463832855, -0.05331021174788475, 0.16798999905586243, -0.0444166362285614, 0.12679950892925262, 0.23804163932800293, 0.13240906596183777, 0.13034866750240326, -0.15042969584465027, 0.1448632776737213, -0.21082893013954163, 0.1251121163368225, -0.12327465415000916, 0.016413133591413498, -0.056027501821517944, -0.13825759291648865, -0.014494679868221283, 0.018149930983781815, 0.031199712306261063, 0.08303830772638321, 0.05585004761815071, -0.11970716714859009, 0.03701110929250717, 0.14069616794586182, 0.04285988211631775, -0.0015001576393842697, 0.03249775618314743, -0.0077398959547281265, 0.07449227571487427, -0.025888480246067047, 0.08007825911045074, -0.11370082944631577, 0.11689102649688721, 0.08929427713155746, -0.0054343342781066895, 0.1636916995048523, -0.09289002418518066, -0.012171301990747452, 0.0002603528555482626, -0.054768916219472885, 0.019092023372650146, -0.14479312300682068, -0.2035427838563919, 0.061067432165145874, -0.03983154892921448, -0.18805432319641113, 0.14489224553108215, 0.01657126098871231, 0.01322642620652914, 0.06890416890382767, 0.12928664684295654, -0.11351026594638824, -0.0936831533908844, 0.08578246086835861, -0.11912545561790466, -0.088679239153862, 0.022767357528209686, -0.17193573713302612, 0.095279760658741, 0.049301061779260635], "changes": {"1wk": -9.565220708432404}}, {"text": "Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Corvus Pharmaceuticals, Inc. Mon, Jan 13, 2025, 3:30 PM 10 min read In This Article: CRVS -5.41% Corvus Pharmaceuticals, Inc. Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.\u00a0The data, which include previously reported results from cohort 1 of the trial and new data covering 10 patients with 28-day follow-up from cohort 2 of the trial, demonstrated a favorable safety profile and efficacy profile. This includes significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints of IGA (Investigator Global Assessment) 0 or 1 and EASI (Eczema Area and Severity Index) 75. \u201cAs we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for the treatment of atopic dermatitis,\u201d said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. \u201cThese additional data from cohort 2 evaluating a 200 mg once a day dose appear better than the initial results from cohort 1 reported in December. Using rigorous efficacy endpoints of IGA 0 or 1 and EASI 75, we see clinically meaningful activity of soquelitinib in both cohorts compared to the placebo group, which had no patients achieve these endpoints after four weeks of treatment. We focus on these endpoints because they have been accepted as measurements of clinical benefit and have been used as the basis for regulatory approval for several approved treatments for atopic dermatitis.\u201d Dr. Miller added, \u201cBased on the results to-date, we believe soquelitinib will be attractive to physicians and patients due to its convenient oral administration, safety and novel mechanism of action. It also is well positioned as a potential new treatment option for a broad range of immune disease indications based on its ability to modulate and control parallel signaling pathways in the\u00a0immune system. We look forward to completing enrollment in the atopic dermatitis trial and reporting full results in the second quarter 2025 while also continuing to advance our Phase 3 registration trial in relapsed peripheral T cell lymphoma and other clinical programs.\u201d Soquelitinib New Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial The Company is reporting results from 16 patients in Cohort 1 (12 patients in the soquelitinib group receiving 100 mg orally twice per day vs. four receiving placebo) and 10 patients in Cohort 2 (seven patients in the soquelitinib group receiving 200 mg orally once per day vs. three receiving placebo) for which 28 days of treatment have been completed. For those 19 patients in the soquelitinib group, 26% achieved IGA 0 or 1 and 37% achieved EASI 75; and of the seven in the placebo group, none achieved IGA 0 or 1 or EASI 75 (see Figure 1 below). IGA 0 or 1 and EASI 75 have been determined by the U.S. Food and Drug Administration (FDA) to be clinically meaningful and approvable endpoints and have been the endpoints used in clinical trials for other FDA approved treatments for atopic dermatitis. Story Continues No significant safety issues were observed and no clinically significant laboratory abnormalities were seen. All 10 patients from Cohort 2 completed 28 days of dosing at the full dose of 200 mg orally once per day; the remaining patients from Cohort 2 are at various stages of treatment. Cohort 2 of the trial is fully enrolled (N=16) and the Company plans to report full results from all four study cohorts in the second quarter 2025. Figure 1: Percent Patients Achieving Endpoints IGA 0 or 1, EASI 75 at Day 28 of Treatment Percent Patients Achieving Endpoints IGA 0 or 1, EASI 75 at Day 28 of Treatment The placebo patients from Cohort 1 (n=4) and Cohort 2 (n=3) are combined. Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Design The randomized, double-blind, placebo-controlled Phase 1 clinical trial is planned to enroll 64 patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy. Patients are enrolled into one of four dosing cohorts in a 3:1 ratio (12 active and four placebo) to receive either soquelitinib or placebo. The cohorts are sequentially enrolled and will examine 100 mg orally twice per day, 200 mg orally once per day, 200 mg orally twice per day and 400 mg orally once per day. Patients are treated for 28 days and are then followed for an additional 30 days with no therapy. These doses were selected based on the Company\u2019s prior experience evaluating soquelitinib in T cell lymphoma patients. The doses in the atopic dermatitis trial studied in Cohorts 1 and 2 are lower than the 200 mg orally twice a day dosing regimen, which is the level that has been shown to provide complete ITK occupancy and that is being evaluated in the Company\u2019s ongoing registrational Phase 3 clinical trial of soquelitinib in peripheral T cell lymphoma. The primary endpoints include safety and tolerability. Efficacy, measured by improvement in EASI score and IGA, are secondary endpoints. Reduction in itch and various cytokine biomarkers are exploratory endpoints. EASI scores are also evaluated by the percent of patients that achieve a specified percent reduction in EASI score \u2013 EASI 50 for patients that achieved a 50% reduction; EASI 75 for a 75% reduction; and EASI 90 for a 90% reduction. Corvus and a data monitoring committee monitor the data from the trial as the trial progresses. Upcoming Presentation and Webcast Dr. Miller will present a corporate overview including the new data from Cohort 2 of the soquelitinib Phase 1 clinical trial at the 43 rd Annual\u00a0J.P. Morgan Healthcare Conference on\u00a0Wednesday, January 15\u00a0at\u00a02:15 pm ET /\u00a011:15 am PT. An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Atopic Dermatitis Atopic dermatitis, also called eczema, is a chronic disease that can cause inflammation, redness, scaly patches, blisters and irritation of the skin. It affects up to 20% of children and up to 10% of adults, and treatments include topical therapies, oral therapies and systemic injectable biologic therapies. It is frequently associated with other allergic disorders such as food allergies and asthma. Atopic dermatitis, like asthma and allergy, involves the participation of Th2 lymphocytes which secrete cytokines that result in inflammation. Soquelitinib has been shown in preclinical studies to inhibit cytokine production from Th2 lymphocytes. About Soquelitinib Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial ( NCT06561048 ) of soquelitinib in patients with relapsed PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com . Forward-Looking Statements This press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company\u2019s product candidates including soquelitinib; the outlook for the Phase 1 clinical trial of soquelitinib; physician and patient receptivity to soquelitinib; the potential use of soquelitinib to treat atopic dermatitis and other immune diseases; the Company\u2019s conduct of, enrollment in and timing of clinical trials and results, including the Company\u2019s Phase 3 clinical trial in PTCL and Phase 1 clinical trial in atopic dermatitis; and the potential of ITK inhibition as a new approach to immunotherapy. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cwill,\u201d \u201cmay\u201d or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company\u2019s control. The Company\u2019s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company\u2019s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company\u2019s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company\u2019s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company\u2019s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and other foreign countries; the costs of clinical trials may exceed expectations; and the Company\u2019s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/789edc2f-f3d8-4ffc-80c2-41765cceff02 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2025-01-13T15:30:00", "sentiment": {"score": 0.886939044110477, "confidence": 0.896561324596405, "probabilities": {"positive": 0.896561324596405, "negative": 0.009622280485928059, "neutral": 0.0938163623213768}}, "embedding": [-0.01753935217857361, -0.00282596074976027, 0.024294761940836906, 0.011625811457633972, 0.021888256072998047, -0.0317501425743103, -0.11263429373502731, 0.31208693981170654, 0.023668020963668823, 0.051465123891830444, -0.06359206140041351, -0.05818737670779228, 0.05059687793254852, 0.067365862429142, -0.012381551787257195, 0.08153358846902847, 0.1502607762813568, -0.04959826171398163, 0.030453402549028397, 0.03193347528576851, 0.055785682052373886, -0.015542929992079735, 0.07149557769298553, 0.10373252630233765, -0.1814165711402893, 0.0014813002198934555, -0.1580468863248825, -0.023903673514723778, -0.15568676590919495, -0.12668606638908386, 0.1509828269481659, 0.06853077560663223, 0.0419701486825943, -0.103360116481781, -0.1304493248462677, -0.08984844386577606, -0.1949227750301361, 0.0030602002516388893, -0.057640161365270615, 0.11504102498292923, -0.10969635844230652, 0.014638273976743221, -0.214583158493042, 0.04159609228372574, 0.0076407804153859615, -0.2602505683898926, -0.07455453276634216, 0.16438667476177216, 0.010552946478128433, 0.23124605417251587, -0.06659457087516785, -0.08925341069698334, 0.0005195150151848793, 0.07205890119075775, -0.09258842468261719, 0.14602243900299072, -0.25297224521636963, -0.053453005850315094, 0.02656160667538643, 0.1484505832195282, -0.07675690203905106, -0.16796308755874634, -0.0020156819373369217, -0.0268179289996624, 0.10872317850589752, 0.06494880467653275, 0.06530280411243439, -0.10961808264255524, 0.011443118564784527, 0.0693022608757019, -0.03144220635294914, -0.09464074671268463, -0.037104859948158264, 0.20205548405647278, -0.005962899886071682, 0.055889204144477844, 0.039481405168771744, 0.117302805185318, 0.0027328478172421455, -0.08953022956848145, 0.1310204416513443, 0.10429944097995758, 0.055863916873931885, 0.03847016021609306, 0.03700996935367584, -0.10891596972942352, 0.015088366344571114, 0.14046496152877808, 0.09122087061405182, -0.01604931429028511, 0.24358104169368744, 0.05184826999902725, -0.06881000101566315, 0.012722054496407509, 0.1761358231306076, -0.04231434315443039, -0.0711275264620781, 0.09859627485275269, 0.08576855063438416, -0.05664490908384323, 0.02247459627687931, -0.15216746926307678, -0.12915079295635223, -0.10690715163946152, -0.03991549462080002, -0.11711902916431427, 0.16618704795837402, -0.1837436556816101, 0.017465127632021904, 0.13874568045139313, 0.021315820515155792, 0.04248785972595215, -0.023186810314655304, -0.07383313775062561, -0.09915776550769806, 0.17690463364124298, 0.15321752429008484, 0.13379856944084167, 0.22436010837554932, -0.10177846252918243, 0.14341893792152405, -0.021313242614269257, 0.10183188319206238, -0.18783345818519592, 0.05659697949886322, 0.08971697092056274, -0.02445388212800026, 8.985807956103796e-33, -0.07072073966264725, 0.11489725857973099, 0.006137470714747906, -0.020764321088790894, -0.05807443708181381, 0.021685918793082237, 0.03519687056541443, 0.08448134362697601, -0.09064093232154846, -0.14724013209342957, -0.14470401406288147, 0.06854693591594696, 0.039647553116083145, 0.17770829796791077, 0.04928978160023689, 0.0037379758432507515, 0.02392388880252838, 0.02051069773733616, -0.007577262818813324, -0.12316504865884781, 0.02956351265311241, 0.04221423715353012, -0.1213468611240387, 0.11965332925319672, -0.18276964128017426, 0.19755011796951294, 0.057100724428892136, 0.04622556269168854, -0.06268300116062164, -0.033243920654058456, -0.12389615178108215, 0.04035130888223648, 0.014435883611440659, 0.02372385747730732, -0.05213218927383423, 0.027626464143395424, -0.026001404970884323, -0.055912040174007416, 0.05099455267190933, -0.03255016356706619, 0.006667131558060646, 0.0753171294927597, -0.06018861010670662, -0.05127941817045212, 0.015485875308513641, -0.09776481986045837, -0.2468625158071518, -0.018511857837438583, 0.04621514678001404, -0.0033246297389268875, -0.04225761070847511, -0.01820015162229538, -0.08847960829734802, 0.03394141420722008, -0.11881138384342194, 0.20381194353103638, -0.17841774225234985, 0.013147496618330479, 0.11351777613162994, 0.0549691766500473, 0.14968548715114594, 0.025349315255880356, 0.08054295182228088, 0.00482588354498148, -0.018523363396525383, 0.0637306421995163, -0.03811820596456528, -0.042266570031642914, -0.1310875564813614, -0.02103663608431816, 0.009149178862571716, 0.046420663595199585, 0.14891153573989868, 0.16404429078102112, 0.07189929485321045, 0.03141050413250923, 0.07473848760128021, 0.1333208978176117, -0.07264183461666107, -0.012592140585184097, 0.0540924146771431, 0.0016477340832352638, -0.03372194617986679, 0.07561881840229034, 0.04495472088456154, -0.011312294751405716, -0.025785166770219803, 0.050711490213871, -0.201086163520813, -0.0021325526759028435, 0.19540250301361084, -0.07341040670871735, -0.02331557497382164, 0.1142725944519043, -0.08695356547832489, -1.1732222671789419e-32, -0.04073631390929222, -0.014075475744903088, 0.05183594673871994, -0.024968445301055908, -0.027798717841506004, 0.14129342138767242, 0.14483053982257843, -0.06432001292705536, 0.1328931301832199, -0.08212903141975403, -0.01255006343126297, -0.02525324374437332, -0.011983860284090042, -0.11440692842006683, -0.06564761698246002, 0.17051637172698975, -0.03686724603176117, -0.010497359558939934, -0.2460075318813324, 0.04671843349933624, 0.08109620213508606, 0.10625683516263962, -0.027932733297348022, 0.05076415464282036, -0.05424132198095322, 0.01188358198851347, 0.20286968350410461, -0.02199222892522812, 0.033453647047281265, 0.0160671416670084, -0.013787411153316498, -0.053073637187480927, -0.18048852682113647, -0.09486712515354156, -0.033198051154613495, 0.0006685182452201843, 0.010747859254479408, -0.19482286274433136, -0.1038757935166359, -0.054971836507320404, -0.011579524725675583, -0.015340911224484444, -0.09496111422777176, -0.02083965390920639, 0.17802897095680237, 0.03666060045361519, 0.021796846762299538, -0.11829708516597748, 0.03501931205391884, -0.095303475856781, -0.06240563839673996, 0.048607923090457916, 0.031683359295129776, -0.03714292496442795, -0.01964145340025425, -0.1416037231683731, 0.029941149055957794, -0.1471984088420868, -0.07445321977138519, 0.06952189654111862, 0.07934108376502991, 0.08903452754020691, -0.13324838876724243, 0.00659665372222662, 0.08451655507087708, 0.09675803780555725, 0.02786039561033249, -0.19120308756828308, 0.07054329663515091, -0.07606080174446106, -0.16817820072174072, -0.21942517161369324, -0.12696950137615204, -0.1303330957889557, -0.1035216748714447, 0.1860891878604889, -0.03592812642455101, -0.10606888681650162, -0.2247178703546524, -0.03768109530210495, -0.1157008558511734, -0.16328826546669006, 0.04524213448166847, 0.008007371798157692, -0.0076123252511024475, 0.029320698231458664, -0.002595162484794855, -0.11005155742168427, -0.04443850368261337, 0.19969722628593445, -0.0652623251080513, -0.06474575400352478, -0.14727574586868286, 0.17613625526428223, 0.04664767533540726, -1.0111183712524507e-07, 0.24326172471046448, -0.08626417815685272, 0.1374097466468811, 0.026451565325260162, 0.010518509894609451, 0.10914594680070877, -0.06796988844871521, -0.06965955346822739, -0.10046707093715668, 0.09996537864208221, -0.0346057303249836, 0.07359609752893448, -0.06656049937009811, 0.08205379545688629, -0.04134511575102806, 0.018591519445180893, 0.13209304213523865, 0.13163445889949799, -0.015419365838170052, -0.06478580832481384, -0.16490817070007324, -0.029096515849232674, 0.08378629386425018, -0.14298728108406067, 0.07631324231624603, -0.023048128932714462, 0.027880489826202393, 0.2584645450115204, 0.05259431153535843, -0.16688305139541626, -0.07255586981773376, -0.009256463497877121, 0.00498715415596962, -0.008707288652658463, -0.006757496856153011, -0.046260811388492584, 0.1542591154575348, 0.10082010924816132, 0.19474583864212036, 0.15852133929729462, -0.030802663415670395, 0.059358470141887665, -0.04149597883224487, 0.12755367159843445, 0.02633894607424736, -0.06989331543445587, -0.09502817690372467, -0.07894858717918396, 0.04914241284132004, -0.21354639530181885, -0.008852452039718628, -0.015586726367473602, -0.05766325443983078, 0.008295749314129353, -0.09650083631277084, 0.15639202296733856, -0.16749465465545654, -0.07143964618444443, -0.021569469943642616, -0.13515640795230865, 0.0294124074280262, -0.13856545090675354, -0.046680863946676254, 0.020815035328269005], "changes": {"1wk": -3.6538382183162326}}, {"text": "Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Corvus Pharmaceuticals, Inc. Wed, Jan 8, 2025, 12:01 AM 1 min read In This Article: CRVS -5.41% Corvus Pharmaceuticals, Inc. BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that\u00a0Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43 rd Annual J.P. Morgan Healthcare Conference, which is being held in\u00a0San Francisco from January 13-16, 2025. The Company\u2019s presentation will be on\u00a0Wednesday, January 15\u00a0at\u00a02:15 pm ET / 11:15 am PT. An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com . INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2025-01-08T00:01:00", "sentiment": {"score": 0.029638007283210754, "confidence": 0.04241098463535309, "probabilities": {"positive": 0.04241098463535309, "negative": 0.012772977352142334, "neutral": 0.9448160529136658}}, "embedding": [-0.10002857446670532, -0.0281683336943388, -0.10522450506687164, -0.10992857813835144, 0.045888323336839676, -0.025459403172135353, -0.023704668506979942, 0.1879473775625229, 0.05769301578402519, 0.06015314534306526, -0.11307520419359207, 0.04902061074972153, -0.06016527861356735, 0.11520043760538101, -0.06189898028969765, -0.005751396995037794, 0.031326040625572205, -0.0062742894515395164, 0.004534924868494272, 0.04523230716586113, -0.041804198175668716, 0.04818151891231537, 0.0015943263424560428, 0.11640951782464981, -0.07183075696229935, 0.02956617996096611, -0.03929450735449791, -0.002355178352445364, -0.11087144911289215, -0.04435710236430168, -0.014642755500972271, 0.029960783198475838, 0.04498846456408501, -0.03130578249692917, 0.031984589993953705, 0.05029707029461861, -0.10677491128444672, 0.038007572293281555, 0.02215641178190708, 0.033694859594106674, -0.0471121147274971, -0.07654426246881485, -0.10460742563009262, 0.07577142864465714, 0.011195062659680843, -0.15138328075408936, -0.16365838050842285, -0.02349446713924408, 0.007869134657084942, 0.18588802218437195, -0.14696703851222992, -0.01035482157021761, -0.08028291910886765, -0.007869048044085503, -0.10199597477912903, 0.006489118095487356, -0.2072027027606964, -0.0053237262181937695, 0.06852998584508896, -0.07708495855331421, 0.0022364920005202293, -0.0824190303683281, 0.07358427345752716, 0.09219946712255478, 0.06412586569786072, 0.09442994743585587, 0.07454459369182587, 0.012570220977067947, 0.06618138402700424, -0.0038306033238768578, 0.04561561346054077, -0.09388067573308945, -0.04553256183862686, 0.12232805788516998, -0.029618754982948303, 0.11942360550165176, 0.10763131082057953, 0.11220834404230118, 0.11223093420267105, -0.033069271594285965, 0.14068572223186493, 0.08179442584514618, 0.02827131189405918, 0.10377541184425354, -0.08753301203250885, 0.030238108709454536, -0.0017863325774669647, 0.07276057451963425, 0.11368317157030106, 0.0036086097825318575, 0.11025772243738174, 0.008267572149634361, -0.05739302560687065, -0.029448281973600388, -0.05750654265284538, -0.05287577584385872, 0.0147433215752244, 0.05209079384803772, 0.09716217964887619, -0.025285182520747185, -0.030751368030905724, -0.059806033968925476, -0.07855008542537689, -0.08499903231859207, -0.06781784445047379, -0.06765930354595184, 0.04843639209866524, -0.034595564007759094, 0.12889505922794342, 0.05077323690056801, -0.10196614265441895, 0.09902824461460114, -0.025109069421887398, -0.08821222931146622, 0.019241590052843094, 0.26664456725120544, -0.005848310422152281, 0.040175531059503555, 0.2559448182582855, -0.0696953684091568, 0.10058417916297913, -0.03224526345729828, 0.023278841748833656, -0.11844925582408905, 0.03943980857729912, 0.02594122476875782, -0.06423220783472061, 7.487994523653976e-33, -0.06482179462909698, 0.06374669820070267, 0.1911613792181015, 0.06068512052297592, -0.01973208412528038, -0.057929106056690216, 0.09247545897960663, -0.03725340589880943, -0.18522147834300995, -0.09634266793727875, -0.1140141636133194, 0.08995683491230011, 0.06679439544677734, 0.028641637414693832, -0.10007505118846893, -0.058950748294591904, 0.041552748531103134, -0.02683553472161293, -0.10578951984643936, -0.09181369841098785, 0.05382750555872917, 0.07555930316448212, -0.07053882628679276, 0.19499525427818298, -0.03403932973742485, 0.054368555545806885, -0.06062519922852516, 0.1361926943063736, 0.0707424134016037, 0.053591519594192505, -0.17029732465744019, 0.03859522193670273, 0.01920338347554207, 0.04700588807463646, 0.013176270760595798, -0.015934642404317856, -0.15031258761882782, -0.09779245406389236, 0.10605264455080032, -0.03655881807208061, 0.04145733267068863, -0.0349762961268425, -0.1555277556180954, 0.012806200422346592, 0.025764917954802513, -0.03400842100381851, -0.18246525526046753, 0.03558936342597008, -0.08102957904338837, -0.10356730222702026, -0.03019818663597107, 0.04310021176934242, -0.0952577143907547, 0.0346333310008049, -0.006696762982755899, 0.06896211206912994, -0.12030334770679474, -0.08888529986143112, 0.11866720020771027, 0.06164151802659035, 0.065312460064888, 0.0681561604142189, -0.03644079715013504, 0.08105260878801346, -0.02055852673947811, -0.005443442612886429, -0.08143121749162674, -0.06169019266963005, -0.04575767740607262, 0.057378243654966354, 0.03586738929152489, 0.06270049512386322, 0.09752653539180756, -0.0030800271779298782, 0.11934412270784378, -0.020342065021395683, 0.06014798581600189, 0.08945058286190033, -0.04742436856031418, 0.14306151866912842, -0.0018585518701002002, -0.02037171833217144, -0.007876325398683548, 0.07270504534244537, -0.08601631969213486, -0.07952564209699631, 0.005560840014368296, -0.020885586738586426, -0.06565747410058975, 0.010766644962131977, 0.04117221385240555, -0.09752950817346573, -0.02173483371734619, 0.09898372739553452, -0.0739566758275032, -9.576216156851614e-33, 0.06065117195248604, -0.08448626101016998, 0.039808567613363266, 0.0383114330470562, -0.06384436786174774, 0.14764079451560974, 0.17560350894927979, -0.06332804262638092, 0.18051141500473022, -0.0270980317145586, 0.07712925970554352, 0.01052938960492611, -0.024541283026337624, -0.07696264237165451, -0.04311814159154892, 0.1665855050086975, 0.06790722161531448, 0.02667391113936901, -0.12733130156993866, 0.0778980404138565, 0.0289505235850811, 0.14746393263339996, -0.027742499485611916, 0.03016209602355957, -0.051323916763067245, 0.029668644070625305, 0.06084626913070679, 0.06276220828294754, -0.00694348756223917, 0.08131571859121323, -0.03403528779745102, 0.041028983891010284, -0.14912906289100647, -0.045362439006567, 0.015299314633011818, -0.06146763637661934, 0.01836598850786686, -0.16792158782482147, -0.0013303144369274378, -0.1261577606201172, 0.023859187960624695, -0.0947783887386322, -0.02955174632370472, 0.03616242855787277, 0.12296750396490097, 0.05712844803929329, 0.05092776194214821, 0.053111180663108826, 0.06547876447439194, 0.009362367913126945, -0.07630221545696259, 0.05404558777809143, -0.07133501768112183, 0.07078994065523148, -0.015297308564186096, 0.07856530696153641, 0.0025531495921313763, -0.07912493497133255, -0.030289754271507263, 0.0926191508769989, 0.037267349660396576, 0.03449616581201553, -0.04492678865790367, -0.05209270119667053, 0.0824493020772934, 0.05009177327156067, -0.00021228859259281307, -0.011276104487478733, 0.09239362180233002, -0.107784703373909, 0.03672017529606819, -0.06327593326568604, 0.015702269971370697, -0.02519829571247101, 0.006696914788335562, 0.05604470893740654, -0.06658477336168289, -0.13747377693653107, -0.15350620448589325, 0.0008297539898194373, -0.0110807279124856, -0.005358310416340828, 0.04858189821243286, 0.06858092546463013, -0.022339968010783195, 0.05603036656975746, -0.022405005991458893, -0.014931799843907356, -0.0890895202755928, 0.05249965563416481, -0.09312094748020172, -0.14032888412475586, -0.1054697036743164, 0.18402695655822754, 0.0768752321600914, -9.986616333890197e-08, 0.12199610471725464, -0.06987998634576797, 0.06263215839862823, -0.12199939787387848, 0.0147930346429348, 0.03154541552066803, -0.0036219030153006315, -0.05172353237867355, 0.046618133783340454, 0.12612082064151764, -0.04535895213484764, 0.01836174726486206, -0.07352162897586823, 0.03181986138224602, -0.13148169219493866, 0.01616675592958927, -0.06261531263589859, 0.040998995304107666, -0.08971112221479416, -0.1307225525379181, -0.07607312500476837, -0.08709146827459335, 0.10902103036642075, -0.05023207142949104, 0.010066520422697067, -0.0611976683139801, 0.005532197188585997, 0.08173657953739166, 0.01870143413543701, -0.147324338555336, -0.13665936887264252, 0.028314810246229172, 0.010096884332597256, 0.03932328522205353, -0.056847620755434036, -0.0798870176076889, 0.03648119419813156, 0.013900677673518658, 0.09687527269124985, 0.11311281472444534, -0.06994494795799255, -0.03847041353583336, -0.0613168366253376, 0.07816936820745468, -0.037482645362615585, -0.00626619067043066, -0.05674239993095398, -0.026229463517665863, -0.004512217361479998, -0.11067724227905273, -0.04742760211229324, 0.04585876688361168, -0.059440165758132935, -0.05700017511844635, -0.057510681450366974, 0.0903790146112442, -0.03606920689344406, 0.016517318785190582, -0.05908683314919472, -0.1564885824918747, -0.014848423190414906, -0.12982110679149628, 0.09842425584793091, 0.03256535530090332], "changes": {"1wk": -11.304349484650986}}, {"text": "Alphabet, Uber downgraded: Wall Street's top analyst calls The Fly Thu, Jan 2, 2025, 5:39 PM 4 min read In This Article: UBER +0.66% GOOG -1.44% Alphabet, Uber downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Goldman Sachs double upgraded Cloudflare (NET) to Buy from Sell with a price target of $140, up from $77. The firm sees \"several positive catalysts\" for the company to drive improving fundamentals and stock outperformance in 2025. Raymond James upgraded CACI (CACI) to Outperform from Market Perform with a $475 price target. CACI trades at a discount to peers and its historical multiples, but its backlog has expanded and its non-Department of Homeland Security civil government exposure is 6% of sales, contends Raymond James. William Blair upgraded Acuity Brands (AYI) to Outperform from Market Perform, citing an improved company-specific story and upside to estimates given sustainable gross margins following \"impressive\" management execution. Deutsche Bank upgraded RTX (RTX) to Buy from Hold with a price target of $140, up from $131. RTX trades like a defense stock and is valued like a defense stock but compounds EBIT like an aerospace stock, the firm says, adding that this makes RTX an attractive way to play the global defense cycle. DA Davidson upgraded U.S. Bancorp (USB) to Buy from Neutral with a price target of $60, up from $58. After several years of \"meaningful stock underperformance and losing its premium valuation,\" U.S. Bancorp is in the \"early stages of an inflection\" and set to regain positive operating leverage above 0.5%, after missing it seven out of the last eight years, led by an expected rebound in revenue growth and controlling expenses, the firm tells investors in a research note. Top 5 Downgrades: JMP Securities downgraded Alphabet (GOOGL) to Market Perform from Outperform without a price target on the risk of antitrust penalties that could \"significantly impact\" Google's U.S. distribution of search and search revenue. JMP Securities downgraded Uber (UBER) to Market Perform from Outperform without a price target as the rideshare industry transitions to autonomous vehicles. JMP acknowledges Waymo is still too small to materially impact Uber's results, but says the stock's valuation is \"likely to be capped\" until Uber better addresses the transition. Deutsche Bank downgraded Lockheed Martin (LMT) to Hold from Buy with a price target of $523, down from $611. The firm says its lost conviction in its original upgrade thesis from July, and struggles to find new reasons to remain constructive on the shares. Raymond James downgraded L3Harris Technologies (LHX) to Market Perform from Outperform without a price target. Raymond James sees a balanced risk/reward for L3Harris with the company's \"self-help levers\" largely priced into the current valuation. Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of coverage. Biogen remains in transition, as management \"forges ahead\" with the buildout of its Alzheimer's disease franchise, which is an \"uphill battle,\" the firm tells investors in a research note. Story Continues Top 5 Initiations: Janney Montgomery Scott initiated coverage of Norwood Financial (NWFL) with a Buy rating and $31 fair value estimate. While pointing out that the bank competes against larger out-of-state players, the firm thinks Norwood's market share position is \"buildable, especially for a nimble, responsive BHC such as Norwood.\" Barclays initiated coverage of Orchestra BioMed (OBIO) with an Overweight rating and $16 price target. The firm sees a \"series of catalysts\" over the next 12-18 months for Orchestra, which it expects to drive increasing interest and performance in the \"innovative developer of high-impact medical devices.\" H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target. The firm says the company's lead product, soquelitinib, is a first-in-class ITK-specific inhibitor that is being investigated for the treatment of both T cell lymphomas and atopic dermatitis, with potential in a variety of other disorders such as psoriasis, inflammatory bowel disease, and allergic asthma. Canaccord initiated coverage of Kopin (KOPN) with a Buy rating and $2 price target. The firm sees a \"premium multiple\" for the shares as justified \"by several factors.\" BWS Financial initiated coverage of Movado (MOV) with a Buy rating and $31.50 price target. Movado invested in brand ambassadors in 2024, resulting in lower earnings and deletion from the S&P 600, notes the firm, which believes this pullback presents an opportunity given that the investment was not supposed to last for more than a year. Movado has more than $10 a share in cash and a commitment to preserving the cash. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2025-01-02T17:39:30", "sentiment": {"score": 0.9053196832537651, "confidence": 0.9342216849327087, "probabilities": {"positive": 0.9342216849327087, "negative": 0.028902001678943634, "neutral": 0.036876384168863297}}, "embedding": [-0.06766196340322495, -0.13771671056747437, -0.06489934027194977, -0.04093661904335022, -0.04728146642446518, 0.000157512491568923, 0.0871620774269104, 0.1296747922897339, 0.0974438339471817, 0.06824921816587448, -0.016328880563378334, 0.159225732088089, 0.04358697682619095, -0.03698132932186127, 0.053873851895332336, -0.05326351523399353, 0.08084401488304138, -0.05977524444460869, -0.15971186757087708, 0.04154937341809273, -0.05657821148633957, -0.10771875083446503, -0.05575834587216377, -0.08581221103668213, 0.03560478985309601, 0.020813699811697006, -0.08674194663763046, -0.05911504477262497, -0.1509069949388504, -0.16683930158615112, -0.06634826958179474, 0.16474801301956177, 0.046482499688863754, -0.0474853590130806, -0.05784381926059723, -0.03671906143426895, -0.0031629768200218678, 0.07458777725696564, 0.1723441481590271, -0.08466500043869019, -0.026397690176963806, -0.0741678774356842, -0.1564140021800995, 0.038470372557640076, 0.012949005700647831, -0.09319043904542923, 0.0631609559059143, 0.09333816915750504, 0.07579474151134491, 0.011706815101206303, -0.14449934661388397, 0.008435462601482868, 0.039529476314783096, 0.03959942236542702, -0.1361631155014038, 0.07618071138858795, -0.062654048204422, 0.055947501212358475, 0.07884956896305084, -0.022180726751685143, -0.0065395412966609, -0.07061438262462616, -0.021758876740932465, 0.02339768409729004, 0.11207751929759979, -0.04968907684087753, -0.04263802245259285, -0.07974247634410858, -0.08175390958786011, 0.06772041320800781, 0.13592763245105743, -0.06407900154590607, -0.06979349255561829, -0.05829375609755516, 0.06948836147785187, 0.10981307923793793, 0.16671544313430786, -0.005166491027921438, 0.09301790595054626, -0.10630153119564056, 0.09641586244106293, -0.033247075974941254, -0.050472892820835114, -0.05947663635015488, -0.043803587555885315, -0.05948241055011749, 0.08307705819606781, -0.08427432179450989, 0.13828304409980774, -0.012576942332088947, 0.10034206509590149, -0.07289741933345795, 0.06308239698410034, -0.05392615497112274, 0.07032617181539536, 0.009381406009197235, -0.03433776646852493, 0.04179392009973526, 0.004643037915229797, 0.06606874614953995, 0.14730355143547058, 0.10100080072879791, -0.07371893525123596, -0.02267254889011383, -0.07481542974710464, -0.06691275537014008, 0.006761496886610985, 0.0430956669151783, 0.03570856526494026, -0.04240390658378601, -0.10012373328208923, 0.067875437438488, -0.031965307891368866, -0.0913902074098587, -0.11970539391040802, 0.021815765649080276, -0.10481545329093933, -0.03472808003425598, 0.10292556881904602, -0.07235445082187653, 0.018168404698371887, 0.1477145254611969, -0.02025744691491127, 0.02888673171401024, -0.09375325590372086, 0.06679220497608185, -0.15337763726711273, 9.672983586495274e-33, -0.09190791845321655, 0.044007912278175354, -0.09189382195472717, -0.15980499982833862, -0.0692998617887497, -0.031230377033352852, -0.026204943656921387, 0.04469927400350571, -0.11584065854549408, 0.027631912380456924, -0.15185736119747162, 0.11000882089138031, -0.06379981338977814, 0.03945368528366089, 0.13518688082695007, -0.040414951741695404, -0.05754409357905388, 0.007318705320358276, 0.093926802277565, 0.011955874040722847, 0.0549478754401207, 0.07432513684034348, -0.03333903104066849, 0.0017575537785887718, 0.053747471421957016, 0.016868818551301956, -0.00020899344235658646, 0.034638501703739166, -0.03256440535187721, 0.07330548018217087, -0.08221855759620667, 0.017018146812915802, -0.04333673045039177, 0.007666966877877712, 0.009340417571365833, -0.057398997247219086, -0.1395924985408783, -0.04617469757795334, 0.014259977266192436, -0.059123702347278595, -0.13377492129802704, 0.1659853756427765, -0.13431747257709503, -0.04086391627788544, 0.04099307954311371, 0.02191472426056862, -0.05558457225561142, -0.03267689421772957, -0.02352730929851532, 0.006270073354244232, -0.06244198977947235, 0.05396316200494766, 0.0008009701268747449, -0.021664177998900414, -0.1299934983253479, 0.027972625568509102, 0.05878222733736038, -0.03883342072367668, 0.001891949214041233, 0.14460831880569458, 0.026520241051912308, 0.1316966414451599, -0.0461709201335907, 0.06111058220267296, -0.17890745401382446, 0.15861152112483978, 0.03264565020799637, 0.09630776941776276, -0.12657774984836578, 0.1385476291179657, -0.0006423769518733025, 0.018831033259630203, 0.18748925626277924, -0.012703737244009972, 0.08117345720529556, -0.0595909059047699, 0.009495314210653305, 0.042417705059051514, 0.0658881664276123, -0.08705273270606995, -0.03788235783576965, -0.03141266480088234, 0.05893908068537712, -0.01096431165933609, -0.048347555100917816, 0.019191846251487732, 0.016079360619187355, -0.09414294362068176, -0.02628241665661335, 0.0001810230314731598, -0.04810773581266403, -0.07051268965005875, -0.06882363557815552, 0.19580349326133728, -0.009427446871995926, -9.801778829095025e-33, -0.09183810651302338, -0.11849502474069595, -0.025739150121808052, 0.08220396190881729, -0.2018217295408249, 0.028483152389526367, 0.06572436541318893, -0.054279863834381104, 0.001082003116607666, -0.02736358717083931, -0.04879752919077873, 0.10221626609563828, 0.011268229223787785, 0.04468316212296486, -0.0004191538318991661, -0.04906152933835983, 0.07306401431560516, -0.12062712013721466, -0.025029169395565987, -0.05028209462761879, 0.10613219439983368, 0.1862477958202362, -0.12222293019294739, 0.16702279448509216, 0.00015762413386255503, 0.0632636770606041, 0.04536457359790802, 0.15862195193767548, 0.10849036276340485, -0.013067306950688362, -0.04934404417872429, -0.020361745730042458, -0.04081273078918457, 0.13217942416667938, -0.026474013924598694, 0.07921528816223145, 0.07697811722755432, -0.06106863170862198, 0.007987760938704014, 0.0545547753572464, 0.0818888396024704, 0.02478611283004284, 0.08328209817409515, -0.06784529238939285, 0.11718388646841049, 0.059647087007761, -0.03334536775946617, -0.04374478757381439, 0.09867589175701141, -0.023366915062069893, 0.09281300753355026, 0.12053528428077698, -0.03079424798488617, 0.1895698755979538, -0.17485007643699646, 0.050500694662332535, 0.06410038471221924, 0.09095163643360138, -0.01782039925456047, 0.08150584995746613, -0.003270057961344719, 0.12268862128257751, 0.10647962987422943, -0.08257437497377396, 0.02620622329413891, 0.012786295264959335, -0.08889234066009521, -0.09088028967380524, -0.017031393945217133, -0.13617156445980072, 0.05387202650308609, -0.04511960223317146, 0.03482133895158768, -0.07475671917200089, -0.011524250730872154, 0.11156515777111053, -0.04868787154555321, -0.09511442482471466, -0.0805586650967598, 0.022840816527605057, -0.07757116109132767, 0.0772986114025116, 0.013523845002055168, 0.060754209756851196, -0.008635763078927994, 0.08342400938272476, 0.0013523213565349579, 0.0023675505071878433, -0.029930412769317627, 0.020668134093284607, -0.017268536612391472, -0.17688685655593872, -0.06838294118642807, 0.032080769538879395, -0.07666134834289551, -1.0020192320325805e-07, -0.01692390628159046, 0.01891392469406128, 0.10103972256183624, 0.06331418454647064, 0.12345638871192932, -0.044091545045375824, 0.013042640872299671, 0.030278315767645836, 0.04662742465734482, 0.03785276412963867, 0.08186851441860199, 0.003361842595040798, -0.19426381587982178, 0.09031970798969269, -0.08404660224914551, 0.03274858742952347, -0.17264941334724426, -0.0677768886089325, 0.0008477959781885147, -0.054677899926900864, 0.020621631294488907, 0.05109599232673645, 0.04426063597202301, -0.004593793302774429, 0.04902796074748039, -0.07028980553150177, 0.030975505709648132, 0.015133732929825783, 0.044960107654333115, 0.012738751247525215, -0.11943724006414413, 0.028994878754019737, 0.08750681579113007, -0.07193892449140549, 0.06614843010902405, -0.015065641142427921, 0.10169932246208191, 0.005357563495635986, 0.024501625448465347, 0.17408083379268646, -0.03709864616394043, -0.07957149296998978, -0.0505429208278656, -0.032239705324172974, 0.044262006878852844, -0.0664801225066185, -0.18761613965034485, 0.0217732023447752, 0.1287638247013092, -0.17155687510967255, 0.08940152078866959, -0.020047692582011223, -0.020377952605485916, 0.1409294605255127, 0.04545782133936882, -0.08148545771837234, -0.19248422980308533, -0.07473134249448776, -0.09454509615898132, 0.05422345548868179, 0.06887252628803253, -0.20380881428718567, -0.004113633185625076, 0.05218631774187088], "changes": {"1wk": 4.051570423274221, "1mo": -1.2891288588794676}}, {"text": "PREMIUM Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell MT Newswires Wed, Dec 18, 2024, 4:31 PM 1 min read In This Article: CRVS -5.41% Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-12-18T16:31:56", "sentiment": {"score": 0.010362822562456131, "confidence": 0.06461530178785324, "probabilities": {"positive": 0.06461530178785324, "negative": 0.05425247922539711, "neutral": 0.8811322450637817}}, "embedding": [-0.1246396005153656, -0.04954139515757561, 0.019405115395784378, 0.0856669545173645, 0.2821442186832428, -0.024744709953665733, -0.030300699174404144, 0.1217283308506012, -0.12495976686477661, 0.09562010318040848, 0.027147039771080017, 0.08378292620182037, 0.06789843738079071, 0.08492777496576309, 0.015764687210321426, -0.03799916058778763, 0.11663896590471268, -0.142506942152977, 0.026350025087594986, -0.025035575032234192, -0.16807083785533905, -0.012000273913145065, 0.04888036102056503, 0.057698316872119904, -0.03708747774362564, -0.000679393473546952, -0.20841652154922485, -0.016038239002227783, 0.026495344936847687, -0.05552229657769203, 0.019270405173301697, -0.07678375393152237, 0.07574151456356049, -0.021552972495555878, -0.13853459060192108, -0.11111943423748016, -0.10815807431936264, -0.0649745762348175, -0.007837947458028793, 0.1606607288122177, -0.02969655767083168, -0.10405620187520981, -0.25514334440231323, 0.13734790682792664, -0.025536473840475082, -0.10061439871788025, -0.0549255795776844, 0.07121778279542923, 0.040671076625585556, 0.1716359257698059, -0.11031171679496765, -0.09713780879974365, 0.08913403004407883, -0.11426999419927597, -0.1252816915512085, 0.055484045296907425, -0.3451116979122162, -0.1417640745639801, -0.00639007706195116, -0.004501813556998968, -0.03618061542510986, -0.22507382929325104, -0.07159232348203659, 0.06328795105218887, 0.008124084211885929, 0.027843065559864044, 0.05671272054314613, 0.12466026097536087, 0.02847233973443508, -0.04021501913666725, -0.03530250862240791, 0.009731482714414597, -0.06482265144586563, 0.03687144070863724, 0.05876662954688072, 0.3055771589279175, 0.08996101468801498, -0.12111765891313553, 0.0595724917948246, -0.07790101319551468, 0.04306354373693466, 0.010780006647109985, 0.08029409497976303, 0.043852511793375015, 0.015387915074825287, -0.05614962801337242, 0.01640217751264572, -0.06259545683860779, -0.023472541943192482, -0.18494772911071777, 0.19056491553783417, -0.05214585363864899, 0.04617267847061157, 0.02212478592991829, -0.02797980047762394, 0.10639729350805283, -0.2024180293083191, -0.00990950409322977, -0.008676973171532154, -0.0027891509234905243, -0.10507416725158691, -0.07885878533124924, -0.005266749765723944, 0.0032992528285831213, -0.07816290855407715, -0.25384265184402466, 0.06585557013750076, 0.09337969869375229, 0.04404520243406296, 0.18077339231967926, 0.04987754672765732, 0.11840347945690155, 0.06929527968168259, -0.21632879972457886, -0.006449418142437935, 0.21528275310993195, -0.09888667613267899, -0.010738514363765717, 0.2694544792175293, -0.012247988022863865, 0.16770417988300323, -0.03801274672150612, -0.010649798437952995, -0.12334968894720078, 0.051611170172691345, -0.0085008405148983, 0.04195566475391388, 1.1961833452703475e-32, -0.10943329334259033, 0.22246596217155457, 0.07629319280385971, -0.058615293353796005, -0.03389853611588478, 0.008179614320397377, -0.005069154314696789, -0.08684633672237396, -0.0893997773528099, -0.08486675471067429, -0.1655864715576172, 0.2956825792789459, 0.008082781918346882, 0.09019052237272263, -0.03543863072991371, -0.03267313167452812, -0.0012426977045834064, 0.11410831660032272, 0.0055093914270401, -0.03662873059511185, 0.08105668425559998, -0.027901852503418922, -0.08009279519319534, 0.10841311514377594, -0.15769782662391663, 0.17115110158920288, 0.07435151189565659, -0.02968178689479828, 0.10757555067539215, 0.03510935232043266, -0.1660996526479721, 0.13299113512039185, 0.03239600360393524, 0.03494023531675339, 0.02281784638762474, 0.2107701450586319, -0.07609741389751434, -0.03297652304172516, -0.04968637228012085, -0.1104312539100647, 0.08481235802173615, -0.037922460585832596, -0.050345528870821, -0.06351734697818756, 0.005701235495507717, -0.06801187247037888, -0.28197458386421204, -0.1402466893196106, -0.00044383027125149965, -0.1576302945613861, -0.08909036219120026, 0.11544978618621826, -0.16164962947368622, 0.031768858432769775, -0.07329674810171127, 0.11267361044883728, -0.041159264743328094, -0.10244935005903244, 0.1060309186577797, -0.05656258761882782, 0.16911719739437103, 0.0017830218421295285, 0.07624182105064392, -0.0922316238284111, -0.08017851412296295, 0.028177930042147636, -0.0770580992102623, -0.1685958057641983, -0.07858859747648239, 0.15482985973358154, 0.17855627834796906, 0.12581461668014526, -0.015248541720211506, 0.06520681083202362, 0.035477519035339355, 0.11212758719921112, -0.040635231882333755, 0.03625016659498215, 0.11161070317029953, 0.08062779158353806, 0.07007604837417603, 0.002268669195473194, 0.12679167091846466, 0.08089733123779297, 0.057057879865169525, 0.06668642908334732, -0.10563183575868607, 0.09856779128313065, 0.01434049941599369, 0.054089948534965515, 0.13625138998031616, 0.04365764930844307, -0.020548658445477486, 0.1791655421257019, -0.23176033794879913, -1.4575321797830175e-32, -0.10676466673612595, -0.025619031861424446, -0.004444476682692766, -0.004094833508133888, -0.15647144615650177, 0.08825859427452087, -0.02613283507525921, 0.2411237359046936, 0.17498600482940674, 0.14152854681015015, 0.13846226036548615, -0.042468342930078506, -0.08184639364480972, 0.016062935814261436, 0.06799735873937607, 0.12492593377828598, 0.06191607192158699, -0.0018549308879300952, -0.16485488414764404, 0.07141975313425064, 0.012503191828727722, 0.1323387771844864, -0.09063199907541275, 0.25701847672462463, 0.031128177419304848, -0.028356552124023438, 0.10428428649902344, 0.03620953485369682, 0.006535667926073074, -0.02436770312488079, -0.13864709436893463, -0.08839631080627441, -0.11018233001232147, 0.022615406662225723, -0.003939862363040447, -0.05236427113413811, 0.07704334706068039, -0.04074619337916374, -0.02037515863776207, -0.00950564257800579, 0.14446209371089935, -0.12043257802724838, -0.04607386887073517, 0.0019904053770005703, 0.1707630753517151, 0.010184411890804768, 0.07255425304174423, -0.012063480913639069, 0.026859160512685776, -0.05211290717124939, -0.029987892135977745, -0.012592035345733166, 0.05323401466012001, -0.014395216479897499, -0.03231846168637276, 0.04869013652205467, -0.009716272354125977, -0.08524775505065918, -0.03346665948629379, 0.10087470710277557, 0.12207122892141342, 0.11161370575428009, -0.33302512764930725, -0.03704563155770302, 0.04795365035533905, 0.11993162333965302, -0.04174046590924263, -0.20228704810142517, 0.07059765607118607, -0.04713071510195732, -0.0827958807349205, -0.14882813394069672, -0.16396480798721313, -0.2594244182109833, -0.011594254523515701, 0.11855187267065048, -0.09368052333593369, 0.0062835742719471455, -0.17750020325183868, 0.026857176795601845, -0.061211131513118744, -0.1578349769115448, 0.0523686520755291, 0.029928075149655342, 0.011050449684262276, -0.06675632297992706, -0.014348705299198627, -0.21694055199623108, -0.13948392868041992, 0.0788441002368927, -0.21170632541179657, -0.12758812308311462, -0.22167198359966278, 0.14324086904525757, 0.03895170986652374, -1.0034103326006516e-07, 0.1700965017080307, -0.03193898871541023, 0.16912348568439484, 0.030594171956181526, 0.07520907372236252, 0.12392018735408783, -0.03730103000998497, -0.06945014744997025, -0.020112616941332817, 0.2650310695171356, -0.1340615600347519, -0.03719770908355713, -0.04107240214943886, 0.01915888860821724, -0.060757365077733994, 0.1044423058629036, 0.11696826666593552, 0.20094233751296997, -0.03252874314785004, -0.1986125111579895, 0.002696363488212228, 0.09638382494449615, 0.23186947405338287, -0.09138988703489304, -0.023958273231983185, -0.007212439551949501, 0.017282895743846893, 0.15831561386585236, 0.11018015444278717, -0.1474548727273941, -0.1740683615207672, 0.05682401359081268, -0.013896817341446877, 0.014162425883114338, -0.0734260156750679, -0.011904986575245857, 0.1931079626083374, 0.07449153810739517, 0.10602440685033798, 0.09872862696647644, -0.034917689859867096, 0.01689213514328003, -0.007362802047282457, 0.09380864351987839, -0.07036280632019043, -0.008785983547568321, -0.13117314875125885, -0.20295369625091553, 0.08689176291227341, -0.220503032207489, 0.05630932375788689, -0.0961538776755333, 0.08887187391519547, 0.07468212395906448, -0.13541291654109955, -0.002853977493941784, -0.02611662447452545, -0.08481838554143906, -0.10399680584669113, -0.03916586562991142, 0.07692357897758484, -0.2217845767736435, -0.041022080928087234, 0.07920414954423904], "changes": {"1wk": 4.2553254089081705, "1mo": 0.6383023622513776}}, {"text": "Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? Vandana Singh Wed, Dec 18, 2024, 9:23 PM 2 min read In This Article: CRVS -5.41% Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis . The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy. These doses were selected based on the company\u2019s prior experience evaluating soquelitinib in T-cell lymphoma patients. The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days. The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients. EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo. The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group. At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1. At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1. No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery. Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday. Read Next: United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-12-18T21:23:45", "sentiment": {"score": -0.18716825544834137, "confidence": 0.33399173617362976, "probabilities": {"positive": 0.1468234807252884, "negative": 0.33399173617362976, "neutral": 0.5191848278045654}}, "embedding": [0.10220786929130554, 0.05930477753281593, 0.006531338207423687, -0.04471150040626526, -0.027924854308366776, 0.015429329127073288, -0.01584133505821228, 0.3286752700805664, 0.09076061099767685, 0.006566982716321945, -0.021272722631692886, -0.021560367196798325, 0.02267693728208542, -0.025492742657661438, -0.026019077748060226, 0.012911183759570122, 0.1319192796945572, -0.05384424328804016, -0.07028518617153168, -0.0058414507657289505, 0.008358214050531387, -0.045461274683475494, 0.06089155375957489, 0.03568263351917267, -0.03520747274160385, -0.050652340054512024, -0.10290957987308502, -0.02415815182030201, -0.016169603914022446, -0.0544394925236702, 0.06887251138687134, 0.06889393925666809, 0.05520182102918625, -0.07080177962779999, -0.16631962358951569, -0.05526203289628029, -0.22300046682357788, 0.004492688924074173, 0.011728955432772636, 0.10061812400817871, -0.0391850471496582, -0.04939703270792961, -0.15794406831264496, -0.0012712571769952774, -0.0511612668633461, -0.22569741308689117, -0.11695752292871475, 0.08188600838184357, 0.021441921591758728, 0.15980833768844604, -0.0997239351272583, -0.05324237421154976, -0.03649333864450455, 0.02279406413435936, -0.16752572357654572, 0.036552611738443375, -0.24511852860450745, -0.005480105523020029, 0.018642302602529526, 0.14468327164649963, -0.051959410309791565, -0.07709772139787674, -0.001672504236921668, 0.017404625192284584, 0.07910233736038208, 0.010053574107587337, 0.0339457243680954, -0.08864911645650864, -0.009097573347389698, 0.06576357036828995, 0.06895904242992401, -0.08091508597135544, -0.06057132035493851, 0.08055063337087631, -0.03432497754693031, 0.017804386094212532, 0.026209335774183273, 0.04458209499716759, -0.014943260699510574, -0.027606960386037827, 0.0711594969034195, 0.11344917118549347, 0.05627892538905144, 0.028362292796373367, -0.013765919022262096, -0.07954811304807663, 0.01498904824256897, 0.16865932941436768, 0.07593455910682678, -0.0019767573103308678, 0.23334439098834991, 0.050601501017808914, -0.1314089596271515, -0.015723802149295807, 0.10824832320213318, -0.049629710614681244, -0.05429556965827942, 0.11076144129037857, 0.04668916016817093, -0.02857665717601776, 0.015536792576313019, -0.10015623271465302, -0.16617998480796814, -0.04477183520793915, -0.0766095519065857, -0.09641145169734955, 0.13321846723556519, -0.15896902978420258, -0.025299418717622757, 0.04930870980024338, -0.08548184484243393, 0.08053842186927795, -0.061952635645866394, -0.06694258004426956, -0.13055580854415894, 0.20750126242637634, 0.09302143007516861, 0.05526331067085266, 0.1492297351360321, -0.08456583321094513, 0.10243982076644897, -0.038018327206373215, 0.09735330194234848, -0.134834423661232, 0.06843075901269913, 0.09083477407693863, 0.033682793378829956, 1.6165532024990504e-32, -0.013067204505205154, 0.058905214071273804, -0.006280167959630489, -0.07528510689735413, -0.046984147280454636, 0.05148041993379593, 0.10647106170654297, -0.04437103495001793, -0.04682420939207077, -0.10473603010177612, -0.14901311695575714, 0.03850244730710983, 0.03425855189561844, 0.07984550297260284, 0.03410616144537926, 0.0191873200237751, 0.03692144155502319, -0.00038918363861739635, -0.007506672292947769, -0.03891656920313835, -0.028380896896123886, 0.009613052010536194, -0.11493396759033203, 0.09205269813537598, -0.1340906172990799, 0.12669320404529572, 0.002787364646792412, 0.041359104216098785, -0.03870595619082451, -0.019445430487394333, -0.0017442178213968873, 0.02879410609602928, -0.025797806680202484, 0.008840366266667843, -0.04027251899242401, 0.03533212095499039, -0.028189582750201225, 0.020695148035883904, 0.12446743249893188, -0.06228203698992729, -0.006583355367183685, 0.09715187549591064, -0.027897905558347702, -0.07953236997127533, 0.03852511942386627, -0.05577882379293442, -0.1725740134716034, -0.08735902607440948, -0.014824790880084038, 0.041510194540023804, -0.0450405552983284, -0.01515946350991726, -0.022550353780388832, 0.011908173561096191, -0.09511107206344604, 0.08622966706752777, -0.14870519936084747, 0.022993849590420723, 0.011720327660441399, 0.1147274449467659, 0.08055566996335983, 0.0016311714425683022, 0.0993044376373291, 0.029203061014413834, -0.009947586804628372, 0.038817714899778366, -0.09516239166259766, -0.13010743260383606, -0.1374247521162033, 0.007447473239153624, 0.015899227932095528, 0.01130614336580038, 0.12960052490234375, 0.06673039495944977, 0.11008413881063461, 0.02503492683172226, 0.03985367715358734, 0.09822951257228851, -0.03374564275145531, 0.03394525498151779, 0.04450763389468193, -0.02591778337955475, 0.009451217949390411, 0.03063228167593479, 0.05010034143924713, 0.021965961903333664, -0.08533436805009842, 0.007065144367516041, -0.0702696144580841, 0.02849625051021576, 0.0690905824303627, -0.05342954024672508, -0.03588726371526718, 0.07492336630821228, -0.03478505089879036, -1.7644926930330877e-32, -0.02271914854645729, 0.02655668742954731, 0.04640595242381096, -0.009849575348198414, 0.019182909280061722, 0.1158086359500885, 0.08555060625076294, -0.03697741776704788, 0.07769809663295746, 0.018447522073984146, 0.07853683829307556, 0.04569319635629654, -0.057903338223695755, -0.0835849791765213, -0.11079981923103333, 0.081422358751297, 0.013192517682909966, 0.08684708178043365, -0.1432802528142929, -0.019058600068092346, 0.04247910901904106, 0.13689188659191132, 0.023968137800693512, 0.07586224377155304, -0.018498331308364868, 0.05529046058654785, 0.15654772520065308, 0.01966891437768936, 0.008198674768209457, -0.034642525017261505, -0.0071312738582491875, -0.06972792744636536, -0.10733716189861298, 0.020303349941968918, 0.014794488437473774, -0.05406768247485161, -0.003744702786207199, -0.14161503314971924, -0.058062050491571426, 0.01786978356540203, 0.019138267263770103, -0.030164940282702446, 0.034250348806381226, -0.002370604546740651, 0.15497881174087524, -0.036100804805755615, 0.010190438479185104, -0.1749652922153473, 0.12449667602777481, -0.05372229218482971, -0.014795292168855667, 0.053587500005960464, 0.021389169618487358, 0.019347717985510826, -0.0038957172073423862, -0.0599951297044754, 0.08271781355142593, -0.1381579041481018, -0.10753744840621948, 0.003589681349694729, 0.08712838590145111, 0.11094120144844055, -0.08333639800548553, -0.005302336998283863, 0.0687030553817749, 0.06850268691778183, -0.016437968239188194, -0.139778733253479, 0.05435705929994583, -0.10633698105812073, -0.08090949803590775, -0.1851007044315338, -0.07672800123691559, -0.11799243092536926, -0.056999571621418, 0.1293151080608368, -0.05643024295568466, -0.02647511474788189, -0.08807020634412766, -0.028697874397039413, -0.1652703732252121, -0.10390248894691467, 0.022132154554128647, -0.0031463797204196453, -0.07741587609052658, 0.05302649736404419, -0.045006848871707916, -0.08966553211212158, -0.044428277760744095, 0.11309611797332764, -0.0205285232514143, -0.07893521338701248, -0.026275930926203728, 0.08700575679540634, 0.05440166965126991, -1.0139911665874024e-07, 0.18115168809890747, -0.16999956965446472, 0.07937022298574448, 0.012883354909718037, 0.010929267853498459, 0.06494365632534027, -0.03949577361345291, -0.044328559190034866, -0.036270350217819214, 0.10669901967048645, -0.059673599898815155, 0.12822160124778748, -0.16721104085445404, 0.0357109010219574, 0.002932900795713067, -0.050061047077178955, 0.05065792798995972, 0.08346575498580933, -0.021381918340921402, -0.08612498641014099, -0.049868397414684296, -0.06535027176141739, 0.11127647757530212, -0.10767427086830139, 0.038604091852903366, 0.019574327394366264, 0.07787319272756577, 0.2159881591796875, 0.07523802667856216, -0.09400078654289246, -0.019510159268975258, -0.022023633122444153, 0.05352528765797615, 0.0003275461494922638, 0.008339960128068924, -0.03011244907975197, 0.15021176636219025, 0.03541869670152664, 0.17255114018917084, 0.12231111526489258, -0.07735240459442139, -0.016668669879436493, -0.012818415649235249, 0.10682494193315506, 0.0470796562731266, -0.039822086691856384, -0.10295319557189941, -0.05673234909772873, 0.07228679955005646, -0.252636194229126, 0.016424566507339478, -0.04156939685344696, -0.0461665615439415, -0.026618819683790207, -0.14252503216266632, 0.12811003625392914, -0.11137978732585907, -0.0293729305267334, -0.05486766993999481, -0.16684213280677795, -0.0014049820601940155, -0.10357250273227692, -0.0553547702729702, 0.025850441306829453], "changes": {"1wk": 4.2553254089081705, "1mo": 6.595753876534072}}, {"text": "Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Corvus Pharmaceuticals, Inc. Wed, Dec 18, 2024, 3:30 PM 13 min read In This Article: CRVS -5.41% Corvus Pharmaceuticals, Inc. Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at\u00a08:00 a.m. ET\u00a0/\u00a05:00 a.m. PT BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.\u00a0The data demonstrated a favorable safety profile and efficacy profile, supporting the ongoing development of soquelitinib for atopic dermatitis and the potential of ITK inhibition as a novel mechanism of action for other immune diseases. \u201cWe are pleased with the early results of our soquelitinib Phase 1 atopic dermatitis clinical trial, which show an attractive potential product profile at the lowest dose we are studying,\u201d said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. \u201cThe data show consistent signs of efficacy, combined with a novel mechanism of action, a convenient oral route of administration and a favorable safety profile. This is also supported by an analysis of serum cytokine levels, which show a possible relationship between clinical response and reductions in IL-5, IL-17, IL-31, IL-33 and TSLP, along with a trend for TARC. We believe the data highlights soquelitinib\u2019s potential as a new treatment option for atopic dermatitis and the broader opportunity for ITK inhibition for other immune related diseases. In addition to blocking the production of multiple inflammatory cytokines, soquelitinib may have persistent direct effects on immune cell function that act to regulate aberrant immune responses. We look forward to completing the Phase 1 trial and initiating other trials with soquelitinib for immune diseases.\u201d Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Design The randomized, double-blind, placebo-controlled Phase 1 clinical trial is planned to enroll 64 patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy. Patients are enrolled into one of four dosing cohorts in a 3:1 ratio (12 active and 4 placebo) to receive either soquelitinib or placebo. The cohorts are sequentially enrolled and will examine 100 mg oral twice per day, 200 mg oral once per day, 200 mg oral twice per day and 400 mg oral once per day. Patients are treated for 28 days and are then followed for an additional 30 days with no therapy. Story Continues These doses were selected based on the Company\u2019s prior experience evaluating soquelitinib in T cell lymphoma patients. The doses in the atopic dermatitis trial bracket the 200 mg oral twice a day dosing regimen, which is the level that has been shown to provide complete ITK occupancy and that is being evaluated in the Company\u2019s ongoing registrational Phase 3 clinical trial of soquelitinib in peripheral T cell lymphoma. The primary endpoints include safety and tolerability, and efficacy, measured by improvement in Eczema Area and Severity Index (EASI) score, Investigator Global Assessment (IGA), reduction in itch and various cytokine biomarkers. EASI scores are also evaluated by the percent of patients that achieve a specified percent reduction in EASI score \u2013 EASI 50 for patients that achieved a 50% reduction; EASI 75 for a 75% reduction; and EASI 90 for a 90% reduction. Corvus and a data monitoring committee will be able to monitor the data from the trial as the trial progresses. Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial The Company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 that received soquelitinib 100 mg oral twice per day and four that received placebo) with follow up at 28 days and at 58 days. At 58 days, two patients in the soquelitinib group were not available for follow up. The soquelitinib and placebo patients were well matched; see Table 1 below for patient characteristics. Table 1: Cohort 1 Patient Characteristics Soquelitinib Placebo (N=12) (N=4) Age, mean (range), yrs 46.3 (30\u201366) 50.5 (32\u201362) Gender, male n (%) 7 (58.3) 4 (100) Race/ethnicity, n (%) Asian 2 (16.7) 0 (0) Black or African American 6 (50) 4 (100) White 3 (25) 0 (0) Hispanic or Latino 1 (8.3) 0 (0) Baseline EASI, mean (range) 20.4 (15.0\u201346.6) 18.5 (14.9\u201324.8) Baseline IGA, mean (range) 3.0 (2\u20134) 3.3 (3\u20134) Prior AD therapies, n (%) Topical Corticosteroids 11 (91.7) 4 (100) Systemic therapies 3 (25) 2 (50) Concomitant topical steroids 0 (0) 1 (25) The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to an EASI score of 18.5 and an IGA score of 3.3 for placebo patients. All soquelitinib patients discontinued topical corticosteroids prior to enrollment, while one placebo patient continued topical corticosteroid treatment. All patients, except the one placebo, discontinued topical corticosteroids for at least 27 days prior to enrolling in the study. Cohort 1 included a high proportion of African American patients: 50% of the soquelitinib group and 100% of the placebo group. African Americans with atopic dermatitis are known to have a less favorable prognosis compared to other patient populations. Cohort 1 Efficacy Data The cohort 1 EASI and IGA scores are shown in Table 2 below. EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo. The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group. At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and no patients achieved EASI 75, EASI 90 or IGA 0 or 1. At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50 and no patients achieved EASI 75, EASI 90 or IGA 0 or 1. The timing of EASI improvement in the soquelitinib group indicates that a treatment effect begins early, at eight days, and continues for the remainder of the study. (See Figures 1 and 2 below). All soquelitinib treated patients showed improvement in EASI scores. The small number of placebo patients demonstrates a variable course over the treatment period with no substantial change over the 58-day period. Table 2: Cohort 1 Efficacy Results 4 week (Day 28) 8 week (Day 58) Placebo Soquelitinib Placebo Soquelitinib (N=4) (N=12) (N=4) (N=10) Change EASI Mean % Reduction 27.0 55.9 19.1 69.1 EASI 50 (%pts) 50 75 25 90 EASI 75 (%pts) 0 25 0 40 EASI 90 (%pts) 0 8 0 10 IGA 0 or 1 (%pts) 0 25 0 30 Figure 1: Mean EASI Score Change from Baseline (%) for Soquelitinib Treatment Group (N=12 at day 28 and N=10 at day 58) Mean EASI Score Change from Baseline (%) for Soquelitinib Treatment Group (N=12 at day 28 and N=10 at day 58) Figure 2: Mean EASI Score Change from Baseline (%) for Placebo Group (N=4) Mean EASI Score Change from Baseline (%) for Placebo Group (N=4) Cohort 1 Safety Data No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery. No clinically significant laboratory abnormalities were seen. See Table 3 below. Table 3: Cohort 1 Safety Soquelitinib Placebo (N=12) (N=4) Subjects with adverse events 2* 0 Serious adverse events 0 0 Adverse events leading to study drug discontinuation 0 0 Adverse events leading to death 0 0 Treatment-related adverse events: Nausea (Grade 1) 1 0 *Reported adverse events: Nausea (N=1) and Covid-19 (N=1); both resolved without any dose modification. Serum Cytokine Changes Relationships between reductions in certain cytokines with improvement in EASI scores were observed. Significant cytokines changes were seen for IL-5, IL-17, IL-31, IL-33, TSLP and a trend for TARC in EASI 50 responders (N=9) compared to non-responders (N=3). No such relationships were seen in the placebo group. Cohort 2 Initial Efficacy and Safety Data As of December 16, the Company has enrolled 12 patients in Cohort 2 of the trial (soquelitinib 200 mg oral once per day). As of December 7, Day 28 follow up data is available for three patients with efficacy results consistent with that seen in Cohort 1. No clinically significant laboratory abnormalities or treatment related adverse events have been reported in any of the patients enrolled in Cohort 2. Early Exercise of Common Stock Warrants The Company also announced that Samlyn Capital, a holder of warrants to purchase 3,633,978 shares of common stock, has delivered exercise notices with respect to all of its warrants in advance of the June 30, 2025 expiration date, which will result in cash proceeds to the Company of approximately $12.7 million. Conference Call, Webcast and Presentation Slides Corvus will host a conference call and webcast today,\u00a0Wednesday, December 18, 2024\u00a0from 8:00 \u2013\u00a09:00 a.m. ET\u00a0to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for 60 days. About Atopic Dermatitis Atopic dermatitis, also called eczema, is a chronic disease that can cause inflammation, redness, scaly patches, blisters and irritation of the skin. It affects up to 20% of children and up to 10% of adults, and treatments include topical therapies, oral therapies and systemic injectable biologic therapies. It is frequently associated with other allergic disorders such as food allergies and asthma. Atopic dermatitis, like asthma and allergy, involves the participation of Th2 lymphocytes which secrete cytokines that result in inflammation. Soquelitinib has been shown in preclinical studies to inhibit cytokine production from Th2 lymphocytes. About Soquelitinib Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial ( NCT06561048 ) of soquelitinib in patients with relapsed PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website. About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com . Forward-Looking Statements This press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company\u2019s product candidates including soquelitinib; the potential use of soquelitinib to treat atopic dermatitis and the potential of ITK inhibition as a novel mechanism of action for other immune diseases; and the Company\u2019s conduct of, enrollment in and timing of clinical trials, including the Company\u2019s Phase 3 clinical trial in PTCL and Phase 1 clinical trial in atopic dermatitis. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cwill,\u201d \u201cmay\u201d or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company\u2019s control. The Company\u2019s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company\u2019s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company\u2019s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company\u2019s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company\u2019s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and other foreign countries; the costs of clinical trials may exceed expectations; and the Company\u2019s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b695c700-155b-4d6a-80eb-8bbcd1b8886e https://www.globenewswire.com/NewsRoom/AttachmentNg/f1496538-062f-4dc0-ac1c-0a935bf23cd9 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-12-18T15:30:00", "sentiment": {"score": 0.8841723222285509, "confidence": 0.8933219313621521, "probabilities": {"positive": 0.8933219313621521, "negative": 0.009149609133601189, "neutral": 0.09752850979566574}}, "embedding": [-0.11529179662466049, 0.036542005836963654, 0.030354997143149376, -0.03719714283943176, 0.10073155909776688, 0.006009924225509167, -0.07425595074892044, 0.3180767893791199, 0.0113689498975873, 0.08671344816684723, -0.10795469582080841, -0.11184699833393097, 0.11102255433797836, 0.07553523778915405, -0.02439834363758564, 0.11075642704963684, 0.17715668678283691, 0.05380130559206009, -0.019727081060409546, 0.017247099429368973, 0.0474480502307415, -0.038697078824043274, 0.02289038710296154, 0.10715584456920624, -0.17210537195205688, 0.01548813283443451, -0.09188292175531387, -0.021831165999174118, -0.24809056520462036, -0.11002896726131439, 0.04959734529256821, 0.061530906707048416, 0.07901915162801743, -0.030872851610183716, -0.14456504583358765, -0.03993329033255577, -0.22591611742973328, 0.00567695451900363, 0.0055862125009298325, 0.02760258875787258, -0.08191768825054169, 0.003268592059612274, -0.2761576175689697, 0.025402408093214035, 0.03522254154086113, -0.18664413690567017, -0.0820675641298294, 0.1524616926908493, 0.034165456891059875, 0.2088695466518402, -0.07998163998126984, 0.002312030177563429, 0.020115705206990242, 0.07621617615222931, -0.07281529903411865, 0.1336168646812439, -0.2759658396244049, -0.07057224959135056, 0.009774144738912582, 0.07947227358818054, -0.09104049205780029, -0.18703486025333405, 0.03611861169338226, -0.0286861602216959, 0.13890695571899414, 0.030771546065807343, 0.04032447934150696, 0.017779164016246796, 0.005835575982928276, 0.016309861093759537, -0.06879974901676178, -0.03108975850045681, -0.06849302351474762, 0.2039414793252945, -0.006198905408382416, 0.11786215752363205, 0.03815142810344696, 0.10969360917806625, 0.021256349980831146, -0.1283499300479889, 0.10412856936454773, 0.10057579725980759, 0.1614285707473755, 0.0852852612733841, -0.04114864766597748, -0.0883527621626854, -0.038440678268671036, 0.12421655654907227, 0.14591217041015625, 0.05956445634365082, 0.24463127553462982, -0.015048341825604439, 0.007808155845850706, -0.005354409106075764, 0.14805783331394196, 0.008788714185357094, -0.0513664074242115, 0.08929753303527832, 0.07065273821353912, -0.05357403680682182, -0.03142004460096359, -0.22181564569473267, -0.13623440265655518, -0.12865111231803894, 0.0038532353937625885, -0.12435765564441681, 0.1788410246372223, -0.23197972774505615, 0.05316084623336792, 0.10451515763998032, 0.009160003624856472, -0.022007612511515617, -0.04745550453662872, -0.11354134976863861, -0.054824501276016235, 0.2155551016330719, 0.14817534387111664, 0.05997221916913986, 0.19335034489631653, -0.12035290896892548, 0.22633028030395508, -0.034916769713163376, 0.05383174121379852, -0.12311745434999466, 0.02957243099808693, 0.09207332134246826, -0.005920475348830223, 5.1601762850320465e-33, -0.060892075300216675, 0.11806681752204895, 0.07297012209892273, -0.017605086788535118, -0.051777638494968414, -0.07531198859214783, 0.12677866220474243, 0.0763857513666153, -0.1019783765077591, -0.09118720889091492, -0.22293883562088013, 0.04564530402421951, 0.028348930180072784, 0.11455807089805603, -0.004659505560994148, -0.004856664687395096, 0.021114693954586983, -0.021239299327135086, 0.028672877699136734, -0.14412030577659607, 0.023736272007226944, -0.002249050885438919, -0.15454208850860596, 0.07198765873908997, -0.18541283905506134, 0.2071707546710968, 0.08720391988754272, 0.013399066403508186, -0.02599307894706726, -0.02898428402841091, -0.17367056012153625, 0.08812633156776428, 0.05720161646604538, 0.11366859078407288, 0.03228593245148659, 0.027137313038110733, -0.07289159297943115, -0.04562568664550781, 0.07436162233352661, -0.020899228751659393, -0.0031531741842627525, -0.023387910798192024, -0.12254685163497925, -0.059847693890333176, -0.008735672570765018, -0.07074928283691406, -0.2511157989501953, -0.00998647604137659, -0.011124267242848873, -0.05200265720486641, 0.050872620195150375, 0.011997746303677559, -0.05429414287209511, -0.0077909138053655624, -0.11987705528736115, 0.1649380624294281, -0.12076237797737122, -0.020854175090789795, 0.07555557787418365, 0.09086258709430695, 0.09079954028129578, -0.017130877822637558, 0.03440868481993675, 0.10226994752883911, -0.009706517681479454, 0.10556462407112122, -0.07775633782148361, -0.04076874628663063, -0.1646733582019806, 0.026038406416773796, 0.020207969471812248, 0.05699405074119568, 0.17761434614658356, 0.10825732350349426, 0.085462786257267, 0.10605444759130478, 0.07893973588943481, 0.10929914563894272, -0.08818764239549637, 0.0484481081366539, 0.026415744796395302, -0.007173013407737017, -0.04099813103675842, 0.0917203277349472, 0.005049563013017178, -0.06968922168016434, -0.03176289051771164, 0.014269627630710602, -0.15126049518585205, -0.0568741038441658, 0.1967919021844864, -0.0878961980342865, -0.07706582546234131, 0.204938143491745, -0.10126464068889618, -9.62109506179807e-33, -0.018910128623247147, -0.03333249315619469, 0.023016205057501793, -0.055393777787685394, -0.06238989159464836, 0.2277173548936844, 0.15185540914535522, -0.047054409980773926, 0.10388761758804321, -0.007943708449602127, -0.0023088199086487293, -0.035918377339839935, -0.060461293905973434, -0.05060259997844696, -0.1089722216129303, 0.20101723074913025, -0.04188774153590202, 0.08241358399391174, -0.22963744401931763, 0.043299607932567596, 0.022900715470314026, 0.10539086908102036, -0.05045861378312111, 0.09775309264659882, -0.06021997705101967, 0.022868696600198746, 0.14388234913349152, 0.03950560837984085, 0.03005933202803135, 0.12480446696281433, -0.018799807876348495, -0.05997063219547272, -0.12902812659740448, -0.0778103694319725, 0.04992537945508957, -0.007338186725974083, -0.047029051929712296, -0.19432906806468964, -0.062147483229637146, -0.12165577709674835, -0.03260515630245209, -0.14484351873397827, -0.014867587015032768, 0.04495126008987427, 0.21967250108718872, 0.013698220252990723, 0.015930702909827232, -0.09912136942148209, 0.09666207432746887, -0.14008945226669312, 0.011802276596426964, 0.0442260205745697, 0.05281774327158928, 0.021827246993780136, -0.06594790518283844, -0.02455718070268631, 0.08533967286348343, -0.09964349120855331, 0.009658671915531158, 0.027205832302570343, 0.0216390211135149, 0.03777293860912323, -0.05797865241765976, -0.019710497930645943, 0.06275153905153275, 0.05113515257835388, 0.03084656223654747, -0.14106488227844238, 0.06210566684603691, -0.09858231246471405, -0.08818483352661133, -0.1864495873451233, -0.05667732283473015, -0.11009591817855835, -0.10524968057870865, 0.14678889513015747, -0.003452477976679802, -0.08565784990787506, -0.21327824890613556, 0.08149115741252899, -0.06647785753011703, -0.1403394639492035, 0.05554993078112602, -0.028997153043746948, -0.06843186914920807, 0.006634270306676626, 0.011760779656469822, 0.009102387353777885, -0.03822352737188339, 0.15915346145629883, -0.08031034469604492, -0.05393115058541298, -0.17955198884010315, 0.19962885975837708, -0.013123051263391972, -1.005231737849499e-07, 0.23866203427314758, -0.13329444825649261, 0.12710344791412354, -0.04324261099100113, -0.015183230862021446, 0.14085209369659424, -0.06003393605351448, -0.06537199020385742, -0.033290088176727295, 0.04080142453312874, -0.0500958189368248, 0.08602047711610794, -0.07204440236091614, 0.079875648021698, -0.00262476596981287, 0.02251899614930153, 0.07088407129049301, 0.10869342088699341, -0.028362462297081947, -0.062436074018478394, -0.17078188061714172, -0.0383136160671711, 0.1337469071149826, -0.23939818143844604, 0.09820905327796936, -0.10862725973129272, -0.027932297438383102, 0.20733202993869781, 0.08285403251647949, -0.13301029801368713, -0.0945117324590683, -0.02921503223478794, -0.0434502474963665, 0.026171419769525528, -0.0028999727219343185, 0.024637944996356964, 0.05373293161392212, -0.019151542335748672, 0.23563188314437866, 0.15163148939609528, -0.06443367898464203, 0.10295697301626205, -0.06413469463586807, 0.09312718361616135, 0.03634737432003021, -0.11345366388559341, -0.11827096343040466, -0.12385814636945724, 0.08105890452861786, -0.2369677722454071, -0.035935960710048676, 0.014104446396231651, -0.06098020821809769, -0.011250028386712074, -0.07826382666826248, 0.15584033727645874, -0.15488110482692719, -0.07653288543224335, -0.03900310397148132, -0.18828389048576355, 0.0314054973423481, -0.1573968231678009, -0.011357899755239487, 0.08249685168266296], "changes": {"1wk": 4.2553254089081705, "1mo": 0.6383023622513776}}, {"text": "Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 Corvus Pharmaceuticals, Inc. Wed, Dec 18, 2024, 12:01 AM 3 min read In This Article: CRVS -5.41% Corvus Pharmaceuticals, Inc. Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast. Conference Call, Webcast and Presentation Slides Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET / 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for 60 days. About Soquelitinib Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial ( NCT06561048 ) of soquelitinib in patients with relapsed peripheral T cell lymphoma. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website. Story Continues About\u00a0Corvus Pharmaceuticals Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com . INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-12-18T00:01:00", "sentiment": {"score": 0.018177658319473267, "confidence": 0.03507247939705849, "probabilities": {"positive": 0.03507247939705849, "negative": 0.01689482107758522, "neutral": 0.9480327367782593}}, "embedding": [-0.0993531346321106, 0.05965304374694824, -0.028071848675608635, -0.04039142653346062, 0.09406056255102158, -0.004336054436862469, -0.1234230250120163, 0.253090500831604, 0.007937876507639885, 0.0816301554441452, -0.06464006006717682, -0.03028443083167076, 0.06755625456571579, 0.020493771880865097, -0.08317925781011581, 0.06368020921945572, 0.11443263292312622, -0.013882588595151901, 0.007586769759654999, -0.002736407332122326, 0.050219155848026276, 0.019631460309028625, 0.008764248341321945, 0.013186849653720856, -0.13132846355438232, -0.033257681876420975, -0.1150645911693573, -0.034934528172016144, -0.13735851645469666, -0.11300992965698242, 0.04905722290277481, 0.04874785616993904, 0.03764169663190842, -0.009426183998584747, -0.06414352357387543, -0.07469236850738525, -0.13485179841518402, 0.032817862927913666, 0.003508511697873473, 0.08549223095178604, -0.07782695442438126, -0.05115548148751259, -0.2325560450553894, 0.04781525582075119, -0.029383433982729912, -0.16018497943878174, -0.10590159893035889, 0.12683923542499542, -0.009930236265063286, 0.1691005527973175, -0.13766321539878845, -0.03748023509979248, -0.011071672663092613, 0.10065112262964249, -0.10653840005397797, 0.13465386629104614, -0.22466406226158142, -0.013803263194859028, 0.06517454981803894, 0.0871814489364624, -0.009517889469861984, -0.1076461672782898, 0.021875834092497826, 0.002916951198130846, 0.1564684361219406, 0.05596209317445755, 0.07821382582187653, 0.02898501791059971, 0.031221911311149597, -0.024400819092988968, 0.008927772752940655, -0.02817598357796669, -0.013280189596116543, 0.12394000589847565, -0.040169745683670044, 0.08131398260593414, 0.030576057732105255, 0.11492836475372314, 0.04962281882762909, -0.08458144217729568, 0.11144424974918365, 0.06619931757450104, 0.13279739022254944, 0.07776322960853577, -0.0543021485209465, -0.08428806811571121, 0.01838986948132515, 0.12485058605670929, 0.15110093355178833, -0.023174891248345375, 0.17053596675395966, 0.012035796418786049, -0.06049628555774689, -0.05324496701359749, 0.07343997806310654, -0.03139284998178482, 0.01763259246945381, 0.10530155897140503, 0.10696309059858322, -0.04325239732861519, -0.01883944869041443, -0.18633635342121124, -0.12064195424318314, -0.05837315693497658, -0.05892157554626465, -0.11444088816642761, 0.12255523353815079, -0.10841820389032364, 0.08728954195976257, 0.07186383008956909, -0.05908084660768509, 0.034716710448265076, 0.036301806569099426, -0.14298668503761292, -0.005120475776493549, 0.16197432577610016, 0.12531045079231262, 0.061540670692920685, 0.2125832736492157, -0.13264113664627075, 0.18519695103168488, 0.010943586006760597, -0.010792599990963936, -0.10462608933448792, 0.0952092856168747, 0.05837692320346832, -0.011786352843046188, 8.778527159751548e-33, -0.001002604141831398, 0.06839362531900406, 0.05007398873567581, -0.01189744658768177, -0.016697844490408897, -0.03455347567796707, 0.08898110687732697, 0.051472775638103485, -0.09772494435310364, -0.07362940907478333, -0.1773533821105957, -0.011798032559454441, 0.04686274379491806, 0.06696127355098724, -0.03579769656062126, -0.07248913496732712, -0.019353056326508522, -0.03642354905605316, 0.04415816068649292, -0.10157036781311035, -0.011051126755774021, 0.08527752757072449, -0.1365329623222351, 0.1259901225566864, -0.11718705296516418, 0.21985581517219543, 0.04012981429696083, -0.003542887046933174, 0.029186580330133438, -0.006513509899377823, -0.15916231274604797, 0.02980458363890648, -0.028075529262423515, 0.08408291637897491, 0.010376045480370522, 0.052750103175640106, -0.041856344789266586, -0.0330059677362442, 0.0252763032913208, -0.04539484158158302, 0.062186360359191895, 0.016037026420235634, -0.10597914457321167, -0.06603360921144485, -0.014459626749157906, -0.14751791954040527, -0.21004155278205872, 0.013371532782912254, 0.098578080534935, -0.01282430812716484, 0.03888982534408569, -0.0009132120758295059, -0.12850473821163177, -0.044925641268491745, -0.07770849019289017, 0.18651504814624786, -0.11696617305278778, -0.028979957103729248, 0.07399873435497284, 0.05489537492394447, 0.1929980218410492, -0.052626460790634155, 0.04333202913403511, -0.0059248777106404305, 0.04079968482255936, -0.010886040516197681, -0.10795922577381134, -0.06645950675010681, -0.030397780239582062, -0.006722643505781889, -0.039678655564785004, 0.06973610818386078, 0.20161989331245422, 0.09889257699251175, 0.0784512609243393, 0.12362222373485565, 0.05929100513458252, 0.12847015261650085, -0.09327369183301926, 0.0316019207239151, 0.0084959976375103, -0.05166996270418167, -0.017891423776745796, 0.024677027016878128, -0.016620714217424393, -0.0679546445608139, 0.012475933879613876, 0.07235982269048691, -0.15174391865730286, -0.009286574088037014, 0.13432195782661438, -0.0680539533495903, -0.10438349843025208, 0.13759541511535645, -0.0770002007484436, -9.998719683263853e-33, -0.009465694427490234, -0.06433980911970139, 0.013822334818542004, -0.015820404514670372, -0.04738609492778778, 0.15342897176742554, 0.08047062903642654, 0.03343452885746956, 0.08158968389034271, 0.020946957170963287, 0.025526991114020348, -0.06992283463478088, -0.020836077630519867, -0.08610907196998596, -0.07575830817222595, 0.15259140729904175, -0.02969764731824398, 0.07914575934410095, -0.20850813388824463, 0.08561784029006958, -0.0417289137840271, 0.14414648711681366, -0.08135420083999634, 0.06038884073495865, -0.05428722873330116, 0.05655123293399811, 0.19953157007694244, 0.10098668932914734, 0.022202249616384506, 0.0766710415482521, -0.03927707299590111, -0.06988191604614258, -0.17681273818016052, 0.018211647868156433, -0.020286209881305695, -0.012438012287020683, 0.019424952566623688, -0.15536487102508545, -0.035241514444351196, -0.1490476131439209, 0.04829853028059006, -0.08543606102466583, -0.07028611749410629, 0.0997031182050705, 0.18251264095306396, 0.05001034960150719, 0.024341585114598274, -0.035326529294252396, 0.07979489862918854, -0.10266562551259995, 0.025902478024363518, 0.026585906744003296, 0.029918989166617393, -0.032955050468444824, -0.02487475425004959, -0.07906243205070496, 0.07929906249046326, -0.17117807269096375, -0.04929434135556221, 0.017622049897909164, 0.08129426836967468, 0.0353546179831028, -0.12939628958702087, -0.02581227943301201, 0.13270717859268188, 0.10209892690181732, 0.03178723528981209, -0.15942217409610748, 0.05326338857412338, -0.03963761776685715, -0.07961201667785645, -0.12736459076404572, -0.03523487597703934, -0.11451895534992218, -0.013208203949034214, 0.1175968199968338, -0.06339230388402939, -0.010264506563544273, -0.17164766788482666, 0.018618956208229065, -0.07564529776573181, -0.1210324838757515, 0.06744186580181122, -0.058286152780056, 0.03217132017016411, 0.03906247764825821, 0.027635211125016212, 0.05582299083471298, -0.0283501036465168, 0.08945596218109131, -0.09775171428918839, -0.05952721834182739, -0.14776906371116638, 0.17758536338806152, 0.040123436599969864, -1.0015978091360012e-07, 0.2516690790653229, -0.11702713370323181, 0.06717552244663239, -0.05089634284377098, -0.0032363804057240486, 0.13473528623580933, -0.07203406095504761, -0.06489938497543335, 0.0033598849549889565, 0.0805860087275505, -0.07103133201599121, 0.08711676299571991, -0.05656732618808746, 0.03235820680856705, 0.06775795668363571, -0.003094499232247472, 0.028729934245347977, 0.04973955079913139, -0.047717031091451645, -0.15168142318725586, -0.14327400922775269, -0.06229593604803085, 0.0924282968044281, -0.0992686003446579, 0.09664329141378403, -0.024857904762029648, -0.05112694948911667, 0.18355730175971985, 0.04918033629655838, -0.17831963300704956, -0.08287529647350311, 0.06252042204141617, -0.055260173976421356, -0.04188472405076027, -0.012622012756764889, -0.013827590271830559, 0.10317884385585785, 0.013071957975625992, 0.1991891711950302, 0.12812747061252594, -0.04789566248655319, 0.11145946383476257, -0.1097700446844101, 0.0437205471098423, 0.07629440724849701, -0.0929260179400444, -0.054256319999694824, -0.1205713152885437, 0.0229741670191288, -0.18611064553260803, -0.09469588100910187, -0.0326850563287735, -0.051652535796165466, -0.008204897865653038, -0.10738620907068253, 0.13907861709594727, -0.07565875351428986, -0.0626305639743805, -0.04285058751702309, -0.10057266056537628, 0.03488420695066452, -0.023929383605718613, 0.00599806010723114, 0.06373625993728638], "changes": {"1wk": -33.69417883768263, "1mo": -35.99458586563012}}, {"text": "Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable Zacks Equity Research Fri, Nov 15, 2024, 4:50 PM 3 min read Most of us have heard the dictum \"the trend is your friend.\" And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Our \"Recent Price Strength\" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness. Corvus Pharmaceuticals (CRVS) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for \"trend\" investors. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. CRVS is quite a good fit in this regard, gaining 105.3% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 18.2% over the past four weeks ensures that the trend is still in place for the stock of this biopharmaceutical company. Moreover, CRVS is currently trading at 83% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout. Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Story Continues Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance. So, the price trend in CRVS may not reverse anytime soon. In addition to CRVS, there are several other stocks that currently pass through our \"Recent Price Strength\" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria. This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market. However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies. Click here to sign up for a free trial to the Research Wizard today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corvus Pharmaceuticals, Inc. (CRVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-11-15T16:50:04", "sentiment": {"score": 0.3169237244874239, "confidence": 0.3361532688140869, "probabilities": {"positive": 0.3361532688140869, "negative": 0.019229544326663017, "neutral": 0.6446172595024109}}, "embedding": [-0.061304572969675064, -0.011831467039883137, -0.02268640697002411, -0.049547675997018814, 0.10372603684663773, 0.04006637632846832, -0.04081489145755768, 0.1667746603488922, 0.08917778730392456, 0.06585509330034256, -0.10914741456508636, 0.11731185764074326, -0.05665351822972298, -0.00575559027493, -0.03384542837738991, -0.06918909400701523, -0.052610546350479126, -0.048023127019405365, -0.0706043690443039, 0.06003451347351074, -0.12043184787034988, -0.16586096584796906, 0.017321154475212097, 0.09758417308330536, -0.022168323397636414, 0.08219033479690552, 0.01885511353611946, 0.04673612862825394, -0.06740019470453262, -0.05171993747353554, 0.03186957538127899, 0.1265259087085724, 0.04492076486349106, -0.00046552158892154694, -0.09565898030996323, 0.03943044692277908, -0.06693384051322937, 0.024119339883327484, 0.09541395306587219, 0.06371352076530457, -0.07415914535522461, 0.006842972710728645, -0.10570433735847473, 0.05478353798389435, -0.0004152487963438034, -0.22774049639701843, -0.022847020998597145, 0.012704397551715374, 0.05538398027420044, -0.02718960866332054, -0.2063765823841095, -0.10900145769119263, -0.09900704026222229, 0.0524287149310112, -0.11138251423835754, 0.05714261531829834, -0.13540248572826385, -0.04236198216676712, 0.17079269886016846, -0.04733199626207352, 0.09436600655317307, -0.01044036541134119, 0.0746036022901535, -0.03771284222602844, 0.08697514235973358, -0.058025579899549484, 0.011024595238268375, 0.03767794743180275, 0.03172034025192261, 0.17848801612854004, 0.1217481791973114, -0.032173506915569305, -0.17383834719657898, -0.10198758542537689, 0.019449841231107712, 0.10573005676269531, 0.0634409487247467, -0.06820070743560791, 0.072114497423172, -0.04682926461100578, 0.06171167269349098, 0.029795225709676743, -0.04115527495741844, -0.02515621855854988, 0.034865859895944595, -0.004171045497059822, 0.11589197814464569, -0.05142751336097717, 0.09643331170082092, 0.014873065054416656, 0.07752744853496552, -0.04525744169950485, -0.06193699315190315, -0.06281742453575134, 0.044298771768808365, 0.10505253076553345, -0.052302904427051544, -0.06548428535461426, 0.00011544115841388702, 0.0644121840596199, 0.10216143727302551, 0.06146051734685898, -0.059286173433065414, -0.0625007152557373, -0.020665306597948074, -0.10249744355678558, 0.03688458725810051, 0.047917939722537994, 0.06347239017486572, 0.09128336608409882, -0.14058132469654083, 0.19240355491638184, -0.09282715618610382, -0.04820434749126434, -0.0005605897167697549, 0.1168728619813919, -0.03631167858839035, -0.021496322005987167, 0.050201885402202606, 0.09457281231880188, 0.13317357003688812, 0.018467914313077927, -0.08403962850570679, -0.12060505896806717, 0.06164242699742317, 0.1104644313454628, -0.11320027709007263, 4.8450427799659e-33, -0.044812001287937164, 0.10951104760169983, -0.009702261537313461, 0.02809339202940464, -0.09551839530467987, -0.004488255828619003, -0.02967919036746025, -0.045101240277290344, -0.13570380210876465, -0.06992065161466599, -0.10459310561418533, 0.2245580404996872, -0.030660368502140045, 0.020141568034887314, 0.011958353221416473, -0.15047615766525269, -0.004364898428320885, -0.03129485249519348, -0.005456268787384033, -0.13402393460273743, -0.09920873492956161, -0.07234448194503784, -0.09676332026720047, 0.017117183655500412, -0.018944665789604187, -0.07627838850021362, -0.025133570656180382, 0.07713009417057037, -0.08197109401226044, 0.01705903559923172, 0.016108820214867592, 0.0880543440580368, -0.05391997471451759, -0.07030916213989258, -0.05438544973731041, -0.09573818743228912, -0.08895207941532135, -0.1230854019522667, 0.11409208923578262, -0.015813354402780533, -0.12290681898593903, 0.1241532489657402, -0.1190161257982254, -0.05697419494390488, 0.10286815464496613, 0.04156241565942764, -0.02697852812707424, 0.00614077178761363, -0.17889685928821564, -0.006271747872233391, -0.03863324597477913, 0.03310379013419151, -0.02351025678217411, -0.03804207593202591, -0.16066285967826843, 0.06618016213178635, 0.003878173418343067, -0.1823418140411377, 0.04398262873291969, 0.04720837250351906, 0.040433965623378754, 0.09182581305503845, 0.05685881897807121, 0.032569319009780884, -0.11555150896310806, 0.048590611666440964, -0.03194010257720947, 0.033514440059661865, -0.08800633251667023, 0.16988816857337952, 0.04243769869208336, 0.07598814368247986, 0.08884285390377045, -0.1325531154870987, 0.21180357038974762, -0.05100107938051224, -0.014136570505797863, 0.031129363924264908, 0.020747989416122437, 0.015378815121948719, 0.04770292341709137, -0.08027073740959167, 0.12008467316627502, 0.0059176599606871605, -0.019665464758872986, -0.03547496721148491, -0.08680672943592072, -0.12092934548854828, -0.02997092716395855, 0.019214166328310966, -0.02577795460820198, -0.07628755271434784, -0.006299005821347237, 0.1400642991065979, -0.07762987166643143, -4.7740649616953114e-33, -0.05242740735411644, -0.05775965750217438, -0.018082091584801674, 0.0348210409283638, -0.011246939189732075, 0.07982903718948364, 0.06628735363483429, 0.0207001231610775, -0.03213174268603325, -0.1296747773885727, 0.07748836278915405, 0.02930021658539772, -0.08706086128950119, 0.00967891700565815, 0.01968272030353546, 0.06423905491828918, 0.09677983820438385, -0.04998442530632019, 0.034740038216114044, -0.03886283189058304, 0.06333503127098083, 0.1947217881679535, -0.17166432738304138, 0.12749938666820526, 0.03774802014231682, 0.09895282983779907, -0.04394828528165817, 0.14259105920791626, 0.01150413416326046, 0.006251290440559387, -0.11786819994449615, 0.006674384698271751, -0.01118750125169754, 0.007525804452598095, -0.027712855488061905, 0.06560344249010086, 0.01667695678770542, -0.15184766054153442, 0.0017496063373982906, 0.10168612748384476, 0.1759079098701477, 0.054911814630031586, 0.174467071890831, -0.05627746134996414, 0.03400944918394089, 0.025809817016124725, 0.117764413356781, 0.12117348611354828, 0.13019154965877533, 0.1684485673904419, 0.06865455955266953, 0.05424216389656067, -0.11615114659070969, 0.1174871101975441, -0.008921070955693722, 0.11085319519042969, -0.12811428308486938, -0.00789756141602993, -0.10204306989908218, 0.06448176503181458, 0.012665575370192528, 0.14108304679393768, -0.04323679581284523, -0.04285925254225731, 0.09318363666534424, 0.053864747285842896, -0.033372633159160614, -0.09632771462202072, 0.05876554548740387, -0.06496366858482361, 0.034438468515872955, -0.016598066315054893, 0.014314597472548485, -0.09752154350280762, -0.050895657390356064, 0.08456090092658997, -0.0869138091802597, -0.14163216948509216, -0.07082995772361755, 0.01865721121430397, -0.09857413917779922, -0.01938606984913349, 0.036682505160570145, 0.019615840166807175, -0.13565246760845184, 0.13353966176509857, -0.19959098100662231, -0.003811136819422245, -0.04497649520635605, -0.03589267656207085, 0.018050450831651688, -0.18543943762779236, -0.05265992879867554, 0.00633084075525403, 0.06084536015987396, -9.937367906331929e-08, 0.03069145977497101, -0.04644455388188362, 0.07986392080783844, -0.03220553323626518, 0.18206830322742462, -0.02945219725370407, 0.08498498052358627, -0.06303000450134277, 0.09570913016796112, 0.16551735997200012, 0.07961215823888779, -0.009104291908442974, -0.11341327428817749, 0.09360560774803162, -0.1205965131521225, 0.06409747898578644, -0.06512509286403656, 0.05655322223901749, -0.08632291853427887, -0.15298065543174744, -0.012167016044259071, 0.04289904981851578, 0.10423725098371506, 0.0788097083568573, 0.0367702841758728, -0.030472509562969208, 0.07182865589857101, 0.1315043419599533, 0.02510666847229004, -0.02013174071907997, -0.040138307958841324, 0.015805799514055252, 0.07439959049224854, 0.05410945415496826, -0.0346500426530838, 0.07844684273004532, 0.1214682012796402, 0.04079728201031685, -0.02209947258234024, 0.14226868748664856, -0.016476241871714592, -0.033581316471099854, -0.04742678999900818, 0.016205117106437683, -0.04287731274962425, -0.037397727370262146, -0.03919985145330429, 0.024747785180807114, 0.032101769000291824, -0.20721785724163055, 0.07798892259597778, -0.08293387293815613, 0.050374165177345276, 0.08402300626039505, -0.01459396444261074, 0.010596849024295807, -0.10678277164697647, 0.00391422538086772, -0.14205069839954376, -0.07628422975540161, 0.023121625185012817, -0.16226749122142792, 0.028257345780730247, 0.15207144618034363], "changes": {"1wk": 9.157509626696454, "1mo": -9.89010387598181}}, {"text": "Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... GuruFocus News Wed, Nov 13, 2024, 10:18 AM 3 min de lecture Dans cet article: CRVS -5.41% Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) has initiated a registration phase three trial for peripheral T cell lymphoma (PTCL), which is enrolling patients and progressing as planned. The company has a strong cash position with $41.7 million in cash, cash equivalents, and marketable securities, providing a financial runway into 2026. Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) is advancing its lead program, Socolit, in multiple fronts, including a phase one trial for atopic dermatitis, which has shown no safety signals in the initial cohort. The company has received orphan drug designation and fast track designation from the FDA for Socolit in the treatment of relapsed T cell lymphoma. Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) is exploring a broad range of indications for its ITK inhibitors, including asthma, psoriasis, scleroderma, inflammatory bowel disease, and fibrotic diseases, supported by promising preclinical data. Negative Points Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) reported a significant net loss of $40.2 million for the third quarter of 2024, compared to a $6 million loss in the same period in 2023. The company recorded a non-cash loss of $32.8 million from the change in fair value of its warrant liability during the third quarter of 2024. Research and development expenses increased to $5.2 million in the third quarter of 2024, up from $4 million in the same period in 2023, primarily due to increased clinical trial expenses. The phase one trial for atopic dermatitis is still in early stages, with only the first cohort fully enrolled and follow-up data pending for subsequent cohorts. There is uncertainty regarding the optimal dosing for Socolit in atopic dermatitis, as the disease differs from lymphoma, and the company is still determining the best dose through ongoing trials. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with CRVS. Q : Can you comment on the kinetics of ITK inhibition on clinical scores in atopic dermatitis and expectations for the Easy score improvement after 28 days? A : Richard Miller, CEO: The response kinetics are quick, with improvements seen in about the first week. We expect the criteria for success to be similar to other approved agents like Dupixent, with a durable effect anticipated due to the mechanism of action. Q : How should we think about the follow-up time period for the atopic dermatitis cohorts and the efficacy endpoints? A : Richard Miller, CEO: We will report 28-day data in December. Responses are seen rapidly, within a week. We will evaluate the kinetics and durability of responses over a two-month period as we progress through the cohorts. Lire la suite Q : What is the most typical prior therapy for patients in the atopic dermatitis trial? A : Richard Miller, CEO: Patients have typically failed topical therapies rather than systemic ones. Most have discontinued their topical therapy while on our drug. Q : How do you deal with patients who are complete responders and go on to transplant in the PTCL phase three trial? A : Richard Miller, CEO: Patients who go on to a bone marrow transplant are censored at that point. The number of such patients is anticipated to be small, around 10%. Q : What are your thoughts on the competitive landscape for oral agents in atopic dermatitis? A : Richard Miller, CEO: While many drugs in development are injectables, there are some oral compounds in the clinic. However, I am not in a position to comment on their data or timelines relative to ours. For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . Afficher les commentaires CGU et Politique de confidentialit\u00e9 Privacy Dashboard Articles recommand\u00e9s", "symbol": "CRVS", "date": "2024-11-13T10:18:10", "sentiment": {"score": 0.8988244328647852, "confidence": 0.9195890426635742, "probabilities": {"positive": 0.9195890426635742, "negative": 0.020764609798789024, "neutral": 0.059646349400281906}}, "embedding": [-0.07417654991149902, -0.01601136289536953, -0.07275622338056564, -0.11208528280258179, 0.1082809790968895, -0.08411559462547302, -0.033939726650714874, 0.37111514806747437, 0.16515198349952698, 0.13028699159622192, -0.07161106914281845, 0.052211515605449677, 0.06902875006198883, 0.05891593173146248, -0.015230851247906685, 0.013707904145121574, 0.04998668283224106, -0.019476475194096565, 0.10040019452571869, -0.03494767099618912, -0.030852919444441795, -0.01946248859167099, 0.00827549397945404, 0.08613993227481842, -0.03338155895471573, -0.03183836489915848, -0.09550599753856659, 0.04937664419412613, -0.12337592989206314, -0.0030206963419914246, -0.023988105356693268, 0.10153240710496902, -0.0037411500234156847, -0.03191285580396652, -0.0341213196516037, 0.015934057533740997, -0.2575407028198242, 0.005706584081053734, -0.040149714797735214, 0.03957328572869301, -0.0738333910703659, -0.0697079598903656, -0.2402174472808838, 0.04958678036928177, 0.023060200735926628, -0.23560777306556702, -0.18083173036575317, 0.05985016003251076, 0.03879464045166969, 0.2623593807220459, -0.09455671906471252, -0.12084273993968964, 0.021159157156944275, 0.03140557184815407, -0.19865083694458008, 0.029186317697167397, -0.2023950219154358, 0.016501765698194504, 0.062096234411001205, 0.07161647081375122, -0.007488930597901344, -0.15340183675289154, 0.021610993891954422, 0.0071969665586948395, 0.14994215965270996, 0.05375274643301964, 0.0436411052942276, -0.07472526282072067, -0.04280771687626839, 0.06059359386563301, 0.027392830699682236, -0.07502633333206177, -0.1415705680847168, 0.060013286769390106, -0.06072619557380676, 0.2616026997566223, 0.06744208186864853, 0.09383848309516907, 0.0036248513497412205, -0.043194420635700226, 0.17216740548610687, 0.10242095589637756, 0.045930635184049606, 0.02445743978023529, -0.06650520116090775, 0.019732045009732246, 0.047192104160785675, 0.18812081217765808, 0.13404390215873718, -0.04803789407014847, 0.25306108593940735, 0.011867392808198929, -0.020967788994312286, -0.007236424833536148, 0.0677872896194458, 0.03503645583987236, -0.09973505139350891, 0.0493951216340065, 0.05211974307894707, -0.028868597000837326, -0.03847099840641022, -0.09630593657493591, -0.13161009550094604, -0.16479653120040894, -0.018946489319205284, -0.14103275537490845, 0.13831880688667297, -0.09275177121162415, 0.038375288248062134, -0.0035804356448352337, -0.07113386690616608, 0.08088502287864685, 0.002252595964819193, -0.01789366826415062, -0.010282093659043312, 0.3141982853412628, -0.034149520099163055, 0.05232105404138565, 0.32527297735214233, -0.06314350664615631, 0.19662714004516602, -0.019739074632525444, -0.04952048510313034, -0.1664595603942871, 0.05208646506071091, 0.06552420556545258, -0.12282679229974747, 9.227394820400823e-33, -0.07540909200906754, 0.2208402156829834, 0.09038612246513367, -0.0408749021589756, -0.12717905640602112, -0.0034180069342255592, 0.14947724342346191, -0.04059707373380661, -0.16904067993164062, -0.06996267288923264, -0.19912993907928467, 0.11300423741340637, 0.0060311793349683285, 0.058293409645557404, -0.04944111406803131, -0.028822079300880432, 0.0729045420885086, 0.008862406015396118, -0.0634978786110878, -0.03172559291124344, 0.049888625741004944, 0.014489837922155857, -0.1185469776391983, 0.13976986706256866, -0.10075891017913818, 0.15787088871002197, -0.10934929549694061, 0.017934923991560936, 0.030374430119991302, -0.006483039818704128, -0.15387000143527985, 0.10476106405258179, 0.03293634578585625, 0.0951436311006546, -0.0029612435027956963, -0.0009658448398113251, -0.09396703541278839, -0.05341757833957672, 0.022853640839457512, -0.021362807601690292, 0.019485993310809135, 0.09146574139595032, -0.0640106350183487, -0.09521045535802841, 0.07070381939411163, -0.08036834001541138, -0.1749838888645172, -0.0745915099978447, -0.19108717143535614, -0.08148793131113052, -0.04013936594128609, 0.12248621135950089, -0.13235801458358765, 0.01186457835137844, -0.042601607739925385, -0.003514198586344719, -0.09518864005804062, -0.11340251564979553, 0.10522681474685669, 0.09774179756641388, 0.06022027134895325, -0.07142052054405212, 0.0483410581946373, 0.08495846390724182, -0.03677481412887573, 0.14320412278175354, -0.05808611959218979, -0.10587044060230255, -0.1231527030467987, 0.1525823473930359, 0.07910938560962677, 0.023182200267910957, 0.15158823132514954, 0.044054191559553146, 0.19284099340438843, -0.04668860137462616, 0.10410016030073166, 0.09816691279411316, -0.030888937413692474, 0.015575733035802841, -0.04487566649913788, -0.025364713743329048, -0.0030174581333994865, 0.08824996650218964, 0.02058403193950653, -0.1165475845336914, -0.0738946720957756, 0.034766025841236115, -0.06925566494464874, -0.01762579008936882, 0.033448804169893265, -0.028303023427724838, -0.09827953577041626, 0.25581368803977966, -0.14669185876846313, -9.833530400878674e-33, -0.07492002844810486, 0.06461717188358307, 0.03053998574614525, -0.052090782672166824, -0.12810111045837402, 0.17331676185131073, 0.14246562123298645, 0.0008683018386363983, 0.20463091135025024, -0.00497933104634285, 0.12684065103530884, 0.0018765300046652555, -0.06706579774618149, -0.0872364267706871, -0.01984112523496151, 0.16294628381729126, 0.002477201633155346, -0.06641852855682373, -0.12935462594032288, 0.04773654788732529, 0.0367673859000206, 0.2437313199043274, 0.045273322612047195, 0.16492974758148193, 0.03217257559299469, 0.052627891302108765, 0.0985659584403038, 0.04819166287779808, -0.024873722344636917, 0.025710413232445717, -0.11220795661211014, -0.06070023775100708, -0.09990286827087402, 0.05475294589996338, 0.01780100166797638, -0.0365174300968647, 0.08855295181274414, -0.19813641905784607, 0.017439454793930054, -0.055159736424684525, 0.05512889847159386, -0.10320861637592316, 0.009818101301789284, 0.006478218361735344, 0.11511005461215973, -0.05773720517754555, 0.051478780806064606, -0.025391554459929466, 0.2032327950000763, -0.015765869989991188, -0.04627954214811325, 0.04392930865287781, 0.020539194345474243, 0.03622211515903473, -0.029818175360560417, 0.05879520997405052, 0.04592321813106537, -0.07252038270235062, -0.0831557959318161, 0.09043121337890625, 0.059289101511240005, 0.14955344796180725, -0.09747114777565002, -0.0024226782843470573, 0.1514165997505188, 0.11913476139307022, -0.012039750814437866, -0.0988692194223404, 0.07893623411655426, -0.08305229246616364, -0.05260469764471054, -0.0646558552980423, -0.06687124073505402, -0.1258605718612671, -0.02676638960838318, 0.05310647934675217, -0.06730818003416061, -0.09085962176322937, -0.167462557554245, -0.042391300201416016, -0.08279189467430115, -0.061592184007167816, 0.08519895374774933, 0.0021149422973394394, 0.004179079085588455, 0.05074956640601158, -0.07556042075157166, -0.08111125230789185, -0.08131525665521622, 0.10663938522338867, -0.03620019555091858, -0.11902643740177155, -0.07086662948131561, 0.251772940158844, 0.08750717341899872, -9.976923820431693e-08, 0.20026880502700806, -0.021313413977622986, 0.08120415359735489, -0.05948154255747795, 0.052845995873212814, -0.06659804284572601, -0.01490138191729784, 0.006602824665606022, 0.022811906412243843, 0.20555885136127472, -0.21502426266670227, 0.06998654454946518, -0.10743646323680878, 0.06340715289115906, -0.1706468015909195, 0.06434924900531769, 0.004238062538206577, 0.05481065809726715, -0.05087270215153694, -0.10025131702423096, -0.06672505289316177, -0.07903748750686646, 0.1188124269247055, -0.07037106156349182, 0.009802565909922123, -0.07680798321962357, 0.05301010236144066, 0.16661861538887024, 0.086240753531456, -0.03037281334400177, -0.12091843783855438, -0.02432236447930336, 0.055685751140117645, 0.04188764467835426, -0.08593156933784485, -0.08674512803554535, 0.0697646215558052, 0.02413114905357361, 0.1809711456298828, 0.1529475748538971, -0.06757592409849167, -0.00042651034891605377, -0.016334347426891327, 0.017849210649728775, -0.08670414239168167, -0.09442299604415894, -0.17798103392124176, -0.1446865200996399, 0.07298649847507477, -0.19839966297149658, 0.02380189299583435, -0.0022109164856374264, -0.05199257284402847, -0.04440223425626755, 0.01711294800043106, 0.05654996633529663, -0.06092027574777603, 0.018156565725803375, -0.06554697453975677, -0.20745660364627838, 0.022257385775446892, -0.2654854655265808, 0.06512965261936188, -0.010400887578725815], "changes": {"1wk": -5.298762943548608, "1mo": -8.906425840424157}}, {"text": "PREMIUM Corvus Pharmaceuticals Says Published Soquelitinib Data Highlights Novel Approach to Immunotherapy MT Newswires Thu, Dec 5, 2024, 11:27 AM Dans cet article: CRVS -5.41% Corvus Pharmaceuticals (CRVS) said late Wednesday preclinical data highlighting the potential of soq PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. R\u00e9viser \u00e0 la hausse Vous avez d\u00e9j\u00e0 un abonnement\u00a0? Se connecter CGU et Politique de confidentialit\u00e9 Privacy Dashboard Articles recommand\u00e9s", "symbol": "CRVS", "date": "2024-12-05T11:27:30", "sentiment": {"score": 0.1589809488505125, "confidence": 0.16978217661380768, "probabilities": {"positive": 0.16978217661380768, "negative": 0.010801227763295174, "neutral": 0.8194165229797363}}, "embedding": [-0.11777985095977783, 0.06242753937840462, -0.06731346994638443, -0.014174016192555428, 0.08072885125875473, -0.008522942662239075, -0.04604889079928398, 0.1987142711877823, 0.012047423981130123, 0.06740494072437286, 0.008312185294926167, 0.09930719435214996, 0.07684564590454102, 0.05913911759853363, -0.022795384749770164, 0.013888085260987282, 0.11350512504577637, -0.022303743287920952, 0.06400435417890549, 0.021811440587043762, -0.08220284432172775, -0.056671734899282455, 0.04229651764035225, 0.09356194734573364, -0.003953347448259592, 0.026763280853629112, -0.1678284853696823, -0.11010755598545074, 0.008393132127821445, -0.1346726268529892, -0.002200495917350054, 0.05925019457936287, 0.07001323997974396, -0.0757133811712265, -0.07785843312740326, -0.030899854376912117, -0.024816442281007767, -0.03665022924542427, -0.02095671370625496, 0.12149899452924728, 0.040502697229385376, -0.18929870426654816, -0.14099857211112976, 0.02777533046901226, 0.00427817041054368, -0.10966990143060684, -0.10765422135591507, 0.1269885003566742, -0.05262726545333862, 0.22426870465278625, -0.15067847073078156, -0.10250584781169891, -0.07480669021606445, 0.056823279708623886, -0.08966513723134995, -0.08914391696453094, -0.354167640209198, -0.06514760851860046, 0.03872658684849739, 0.06263596564531326, -0.019233902916312218, 0.0015548759838566184, 0.028177624568343163, 0.10411640256643295, 0.062204509973526, 0.07950908690690994, 0.09099484235048294, -0.0009416392422281206, 0.09379564225673676, -0.1002277135848999, 0.024037444964051247, 0.013760325498878956, -0.03053288720548153, 0.15862597525119781, 0.050270672887563705, 0.15849138796329498, 0.06062209978699684, 0.08044705539941788, 0.09173181653022766, -0.14049427211284637, 0.16488486528396606, 0.03598210588097572, 0.09225446730852127, 0.09696198999881744, -0.023541593924164772, -0.04552755504846573, -0.017814967781305313, 0.034039173275232315, 0.050385456532239914, -0.10413684695959091, 0.17715570330619812, -0.07239247858524323, -0.0005277201998978853, 0.03127333149313927, -0.0601261630654335, 0.04348527640104294, -0.043687205761671066, 0.03113199956715107, 0.06009042263031006, -0.04713814705610275, -0.02291426993906498, -0.1907142847776413, -0.11381533741950989, 0.014668343588709831, -0.056728482246398926, -0.11815019696950912, 0.01566295325756073, -0.08620475977659225, 0.10083659738302231, 0.13228601217269897, -0.07680636644363403, 0.04021749272942543, 0.0111341942101717, -0.20702485740184784, 0.03354965150356293, 0.1318962424993515, -0.028854256495833397, 0.027262955904006958, 0.13295286893844604, -0.1257532685995102, 0.04553576558828354, -0.07693297415971756, -0.08011817932128906, -0.09636861830949783, 0.1913483589887619, 0.0564473532140255, 0.0106112752109766, 2.0521720132570016e-32, 0.012011195532977581, 0.09299709647893906, 0.2138281613588333, 0.01702757366001606, -0.11370395869016647, -0.0006293939659371972, 0.09602873027324677, -0.1015106663107872, -0.16077403724193573, -0.1379016786813736, -0.17296268045902252, 0.1057526245713234, 0.03580616042017937, 0.2063763439655304, -0.018954770639538765, -0.036328740417957306, -0.05798038840293884, -0.011053768917918205, 0.11141280084848404, -0.048983875662088394, 0.05661053583025932, -0.02255333587527275, -0.07081598043441772, 0.19059062004089355, 0.08016997575759888, 0.1605680286884308, 0.0027697915211319923, 0.0020294173154979944, 0.052950676530599594, 0.0474182590842247, -0.12247072160243988, 0.0018172988202422857, -0.022872067987918854, 0.027864648029208183, 0.06471774727106094, 0.09084077179431915, -0.03619047626852989, -0.07175830006599426, -0.0661248043179512, -0.04765365645289421, 0.12267668545246124, -0.023113539442420006, -0.16334514319896698, -0.025133926421403885, -0.012282502837479115, -0.08465808629989624, -0.2464992105960846, -0.10414773970842361, 0.01141918171197176, -0.12023082375526428, -0.00633437093347311, 0.09899896383285522, -0.24482619762420654, 0.05753441900014877, -0.11793413013219833, 0.05508650466799736, -0.11921057850122452, 0.013973423279821873, 0.0646188035607338, 0.04551633074879646, 0.15051250159740448, 0.006091579794883728, 0.11605217307806015, -0.05007409304380417, 0.04645615816116333, -0.01301755290478468, -0.09415726363658905, -0.09799177944660187, -0.05833307281136513, 0.08251910656690598, 0.08530007302761078, -0.025881055742502213, 0.010041287168860435, 0.0056360037997365, -0.034354306757450104, 0.08832395076751709, -0.0605035163462162, 0.04683420807123184, 0.14959180355072021, 0.1099301427602768, 0.004986877087503672, -0.0885860025882721, 0.010842973366379738, 0.11358776688575745, -0.06925947964191437, -0.014605340547859669, 0.044437870383262634, -0.038656868040561676, -0.02688402123749256, 0.10072985291481018, 0.09053376317024231, 0.022195275872945786, -0.061334267258644104, 0.03195031359791756, -0.2016145884990692, -2.2340431767850812e-32, -0.08956039696931839, -0.07523327320814133, 0.012833665125072002, 0.0713709369301796, -0.16557082533836365, 0.03581126406788826, 0.08733072876930237, 0.163270503282547, 0.23534581065177917, 0.08983644843101501, 0.1129835993051529, -0.08458072692155838, 0.037609297782182693, -0.08727297186851501, 0.04974084720015526, 0.12897364795207977, 0.05142662301659584, -0.017599761486053467, -0.1866561472415924, 0.10728602111339569, -0.029232116416096687, 0.08656307309865952, -0.03060678020119667, 0.14226573705673218, 0.07081301510334015, 0.000529190176166594, 0.14117678999900818, 0.03531111404299736, 0.030180444940924644, 0.014379304833710194, -0.11330793797969818, -0.08710039407014847, -0.2160121500492096, -0.05172402784228325, -0.03372102603316307, -0.007927200756967068, 0.16083402931690216, -0.018866615369915962, -0.010137769393622875, -0.2142777144908905, 0.02437073364853859, -0.12397424876689911, -0.19577576220035553, 0.07594644278287888, 0.1537231057882309, 0.013433580286800861, -0.039371903985738754, 0.014171781949698925, 0.1662036031484604, -0.003059698035940528, 0.026948751881718636, 0.04348035901784897, 0.002388941589742899, 0.024042490869760513, -0.09566589444875717, -0.06737490743398666, 0.035001903772354126, -0.1857774704694748, -0.03496408462524414, -0.045520953834056854, 0.07893860340118408, 0.0730702206492424, -0.22702810168266296, -0.11281841993331909, 0.12186691164970398, 0.10249967873096466, 0.061945591121912, -0.1570722758769989, 0.06072951853275299, -0.14605557918548584, 0.002034400589764118, -0.16187430918216705, -0.04392106831073761, -0.16338478028774261, 0.02577049471437931, 0.03251010924577713, -0.0936993733048439, 0.005605056416243315, -0.11704561859369278, 0.069171242415905, -0.012692825868725777, -0.13767109811306, 0.06661173701286316, -0.015773247927427292, 0.11813288927078247, 0.016245462000370026, 0.02763638272881508, -0.08936277776956558, -0.06288843601942062, 0.11637327820062637, -0.1429886519908905, -0.13811366260051727, -0.2315981686115265, 0.1507139652967453, 0.032916128635406494, -1.0103291003815684e-07, 0.17234063148498535, -0.13783957064151764, 0.021856684237718582, 0.019176438450813293, 0.09474604576826096, 0.11037912219762802, -0.14009329676628113, -0.008136413060128689, 0.032079193741083145, 0.1952493041753769, -0.004973060451447964, 0.016235139220952988, -0.02421320043504238, -0.019262155517935753, 0.0878402441740036, 0.042991381138563156, 0.01764250174164772, 0.04168447479605675, -0.04706999287009239, -0.27499184012413025, -0.06433285027742386, -0.016882145777344704, 0.0420585460960865, -0.08128468692302704, 0.1378830522298813, 0.056986384093761444, 0.02510070987045765, 0.06052122637629509, 0.08671902865171432, -0.1509566605091095, -0.15995024144649506, -0.04135074466466904, -0.025806456804275513, -0.002203039824962616, 0.013051026500761509, -0.004448644816875458, 0.17732830345630646, 0.054727084934711456, 0.10125330090522766, 0.019979313015937805, -0.11199123412370682, 0.013464199379086494, -0.050366535782814026, 0.09888732433319092, -0.05943216383457184, -0.03535192459821701, -0.06977036595344543, -0.05429667606949806, 0.0009867232292890549, -0.15410426259040833, -0.011681811884045601, -0.15916986763477325, 0.04867786914110184, 0.026448296383023262, -0.08165587484836578, 0.07342489808797836, -0.019662559032440186, -0.1082332655787468, -0.009819021448493004, -0.06887204945087433, 0.049061134457588196, -0.1277582198381424, 0.08960650116205215, -0.0375417023897171], "changes": {"1wk": -0.24600808711116806, "1mo": -28.290284850666687}}, {"text": "Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% editorial-team@simplywallst.com (Simply Wall St) Wed, Dec 11, 2024, 3:06 PM 4 min read In This Article: CRVS -5.41% Key Insights The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they collectively have a greater say in management and business strategy The top 25 shareholders own 49% of the company Institutions own 15% of Corvus Pharmaceuticals Every investor in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 50% to be precise, is individual investors. Put another way, the group faces the maximum upside potential (or downside risk). Meanwhile, private equity firms make up 16% of the company\u2019s shareholders. In the chart below, we zoom in on the different ownership groups of Corvus Pharmaceuticals. View our latest analysis for Corvus Pharmaceuticals NasdaqGM:CRVS Ownership Breakdown December 11th 2024 What Does The Institutional Ownership Tell Us About Corvus Pharmaceuticals? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Corvus Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corvus Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too. NasdaqGM:CRVS Earnings and Revenue Growth December 11th 2024 Our data indicates that hedge funds own 16% of Corvus Pharmaceuticals. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is OrbiMed Advisors LLC with 11% of shares outstanding. With 8.7% and 7.1% of the shares outstanding respectively, Point72 Asset Management, L.P. and Samlyn Capital, LLC are the second and third largest shareholders. Furthermore, CEO Richard Miller is the owner of 2.7% of the company's shares. Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Story Continues Insider Ownership Of Corvus Pharmaceuticals The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. We can see that insiders own shares in Corvus Pharmaceuticals, Inc.. In their own names, insiders own US$18m worth of stock in the US$524m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. General Public Ownership The general public, who are usually individual investors, hold a 50% stake in Corvus Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private Equity Ownership With a stake of 16%, private equity firms could influence the Corvus Pharmaceuticals board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Corvus Pharmaceuticals better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Corvus Pharmaceuticals you should be aware of, and 1 of them is a bit unpleasant. But ultimately it is the future , not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future . NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRVS", "date": "2024-12-11T15:06:42", "sentiment": {"score": -0.011259831488132477, "confidence": 0.08585382997989655, "probabilities": {"positive": 0.07459399849176407, "negative": 0.08585382997989655, "neutral": 0.8395521640777588}}, "embedding": [0.09254592657089233, -0.14770178496837616, 0.0021899444982409477, -0.1134432703256607, 0.016578031703829765, -0.0619051456451416, 0.020528381690382957, 0.10066519677639008, 0.23683372139930725, 0.07404612004756927, -0.06125125661492348, 0.09232781082391739, -0.02675267681479454, 0.04837726801633835, -0.0862162709236145, -0.07217750698328018, -0.014240698888897896, -0.014550307765603065, -0.11741142719984055, 0.07927628606557846, -0.1782347559928894, -0.1793719083070755, 0.06616177409887314, 0.10251742601394653, -0.01555635966360569, 0.011155194602906704, -0.0779496431350708, -0.03988013043999672, -0.09414814412593842, -0.09239500761032104, -0.01619720086455345, 0.043074458837509155, 0.09434211999177933, 0.023206982761621475, -0.10405623912811279, 0.022139649838209152, -0.10442852973937988, 0.0427686907351017, 0.18405002355575562, 0.08531486988067627, -0.028984423726797104, 0.07317371666431427, -0.006528574042022228, -0.0645756870508194, -0.016477767378091812, -0.1595885455608368, -0.006030983291566372, 0.04387964308261871, 0.05839816853404045, 0.10997727513313293, -0.1369185745716095, -0.014166575856506824, 0.012784390710294247, -0.0009822812862694263, -0.051045406609773636, 0.06833858788013458, -0.22667720913887024, -0.04544466361403465, 0.10931731760501862, 0.047430649399757385, 0.10750506818294525, 0.05048699676990509, 0.05593710020184517, 0.038885749876499176, 0.12373494356870651, -0.006341810803860426, 0.12913727760314941, 0.08741076290607452, -0.07914502173662186, 0.01850936748087406, 0.20046332478523254, -0.096741683781147, -0.12075912952423096, 0.009258335456252098, -0.12418254464864731, 0.15222783386707306, -0.028965743258595467, 0.0850697010755539, 0.05318212881684303, -0.11809912323951721, 0.178005188703537, 0.1504954695701599, 0.027191616594791412, -0.00626421719789505, -0.046045415103435516, 0.0073487283661961555, 0.17021015286445618, -0.03596922755241394, 0.10314484685659409, 0.002502999035641551, 0.03786357492208481, -0.014613241888582706, 0.014405560679733753, -0.11495958268642426, 0.09507650882005692, 0.07844875007867813, -0.09510725736618042, 0.04394914582371712, -0.03210391476750374, -0.008305639028549194, 0.06877206265926361, -0.01396490540355444, -0.1050105094909668, -0.011486593633890152, -0.09410817176103592, -0.12254603207111359, 0.08517738431692123, -0.028101250529289246, 0.06858573853969574, 0.11951801180839539, -0.10647283494472504, 0.2009161114692688, -0.14987006783485413, -0.0502137765288353, 0.030551688745617867, 0.07142230123281479, 0.0042782737873494625, 0.05735982954502106, 0.17463603615760803, -0.017339613288640976, 0.05899032950401306, 0.0018096412532031536, 0.007450669538229704, -0.10424407571554184, 0.09941168129444122, 0.11287425458431244, -0.15816695988178253, 1.2936995648154812e-32, -0.013516456820070744, 0.07675696909427643, 0.09905289113521576, 0.0017149150371551514, -0.12029878795146942, -0.0303206704556942, 0.0037515084259212017, -0.023854302242398262, -0.17829963564872742, -0.09881795197725296, -0.1657538115978241, 0.15093021094799042, 0.005957469344139099, -0.0703234076499939, 0.005687369033694267, -0.046452127397060394, 0.0018920074217021465, -0.019782189279794693, -0.04049400985240936, -0.1253792643547058, -0.09265422821044922, 0.22256705164909363, -0.08538463711738586, 0.06404373794794083, 0.005147572606801987, -0.16153517365455627, -0.1894553005695343, 0.05374542251229286, -0.0759926363825798, 0.017545796930789948, 0.022922953590750694, 0.046892065554857254, -0.06267637014389038, 0.008060202933847904, 0.025365833193063736, -0.06606680154800415, -0.16542014479637146, -0.05515588819980621, 0.08874350786209106, 0.014009137637913227, -0.03369482234120369, -0.004985432140529156, -0.08552764356136322, -0.03217567130923271, -0.07745925337076187, 0.006941199768334627, -0.21189779043197632, -0.03373929485678673, -0.1261838972568512, -0.001588168554008007, -0.06619824469089508, 0.1281891167163849, -0.05540558323264122, 0.01450799684971571, 0.03818932920694351, -0.009734570980072021, -0.02168862521648407, -0.13623645901679993, 0.036347441375255585, 0.07640423625707626, -0.030544284731149673, 0.18152901530265808, -0.031268440186977386, 0.06883443892002106, -0.07622750103473663, 0.10285618901252747, 0.0003069071099162102, 0.07084640115499496, 0.028578754514455795, 0.14323990046977997, 0.0025312663055956364, 0.03289426863193512, 0.00807328149676323, -0.0754040777683258, 0.0555364191532135, -0.06533607095479965, -0.008146812207996845, 0.04525075852870941, 0.017382048070430756, 0.134599506855011, -0.03189675137400627, -0.09307391941547394, 0.11135600507259369, 0.044669345021247864, -0.10526426881551743, -0.04058832675218582, -0.016028665006160736, -0.00691105704754591, -0.016594424843788147, 0.06330548971891403, 0.009829377755522728, -0.07900995016098022, 0.02912934683263302, 0.15260109305381775, -0.1519940346479416, -1.2253109932577699e-32, -0.0020946175791323185, -0.1263594925403595, 0.15050899982452393, -0.051653288304805756, -0.11595623940229416, -0.012218148447573185, 0.06248889118432999, -0.14510126411914825, -0.04018911346793175, -0.14137576520442963, -0.05460638552904129, 0.03744397312402725, -0.019816629588603973, 0.067996546626091, -0.039930690079927444, 0.03901185840368271, 0.15994024276733398, 0.0019348942441865802, -0.01723559759557247, -0.08503517508506775, 0.05068458244204521, 0.12768493592739105, 0.03814242035150528, 0.22215083241462708, 0.014262466691434383, 0.04119469225406647, 0.007861894555389881, 0.06841163337230682, 0.01651322841644287, -0.01854601502418518, -0.07725444436073303, -0.023040927946567535, -0.10336140543222427, 0.02481973171234131, -0.05674868822097778, -0.0053023602813482285, -0.06398019194602966, -0.11311511695384979, -0.019279779866337776, -0.040405191481113434, 0.07978372275829315, 0.03815198689699173, 0.046176426112651825, -0.023847799748182297, 0.07134568691253662, 0.03981943428516388, 0.1255604326725006, 0.02803552709519863, 0.07743526995182037, 0.07959146797657013, -0.025027453899383545, 0.021721627563238144, 0.013005787506699562, 0.12989330291748047, -0.011250627227127552, 0.056802839040756226, 0.025624917820096016, -0.021438118070364, -0.005530674941837788, 0.08201335370540619, 0.08323928713798523, 0.14972800016403198, -0.13213694095611572, 0.12606637179851532, -0.03995092958211899, -0.005809507332742214, -0.08962170779705048, -0.07181526720523834, -0.04465627670288086, -0.0895705297589302, 0.0038451887667179108, -0.21178153157234192, 0.0353529118001461, -0.08549725264310837, -0.08244453370571136, 0.2424221634864807, -0.02815983071923256, -0.16480635106563568, -0.10532264411449432, 0.001983161550015211, 0.020920582115650177, -0.050830550491809845, 0.04772777110338211, 0.07985001802444458, -0.11237508058547974, 0.16949224472045898, 0.003207756206393242, -0.13402093946933746, -0.014790126122534275, 0.02409200742840767, 0.04540406912565231, -0.21284641325473785, -0.003065909259021282, -0.011047979816794395, 0.02349843457341194, -1.0011022766320821e-07, 0.056573159992694855, -0.044004011899232864, 0.1142529845237732, -0.08875921368598938, 0.08553452789783478, -0.06826235353946686, 0.0786108672618866, -0.06491978466510773, 0.06708232313394547, 0.2247043251991272, 0.10570619255304337, 0.017919259145855904, -0.24593539535999298, 0.04856226593255997, -0.07431811094284058, 0.0492115244269371, -0.15275979042053223, 0.0760824978351593, -0.05045418441295624, -0.09906014055013657, 0.02753491885960102, -0.014145039021968842, 0.11265084147453308, 0.019316844642162323, 0.028174685314297676, 0.019081925973296165, 0.010267695412039757, -0.02438606694340706, -0.015317229554057121, 0.07341689616441727, 0.006974550895392895, -0.07202299684286118, 0.09781795740127563, 0.05952955037355423, 0.06327518820762634, 0.04251176863908768, 0.13155300915241241, 0.06489937007427216, 0.01173524558544159, 0.10482122004032135, -0.05815333127975464, -0.045418474823236465, -0.006646080873906612, -0.03004208579659462, 0.003292487934231758, -0.059945203363895416, -0.11003491282463074, 0.06160283833742142, 0.09830352663993835, -0.2268873006105423, 0.09495566785335541, -0.05435498431324959, -0.03799442574381828, 0.0778227299451828, -0.012316743843257427, -0.08022544533014297, -0.09772120416164398, 0.03881850093603134, -0.12531223893165588, -0.14544954895973206, 0.026918713003396988, -0.08487242460250854, 0.0501098670065403, 0.0754506066441536], "changes": {"1wk": -8.87792627215279, "1mo": -30.33291819296701}}]